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A B S T R A C T
Background
Genital Chlamydia trachomatis (C.trachomatis) infection may lead to pregnancy complications such as miscarriage, preterm labour, low
birthweight, preterm rupture of membranes, increased perinatal mortality, postpartum endometritis, chlamydial conjunctivitis and
C.trachomatis pneumonia.This review supersedes a previous review on this topic.
Objectives
To establish themost efficacious and best-tolerated therapy for treatment of genital chlamydial infection in preventingmaternal infection
and adverse neonatal outcomes.
Search methods
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register, ClinicalTrials.gov, theWHO International Clinical Trials
Registry Platform (ICTRP) (26 June 2017) and reference lists of retrieved studies.
Selection criteria
Randomised controlled trials (RCTs) as well as studies published in abstract form assessing interventions for treating genitalC.trachomatis
infection in pregnancy. Cluster-RCTs were also eligible for inclusion but none were identified. Quasi-randomised trials and trials using
cross-over design are not eligible for inclusion in this review.
Data collection and analysis
Two review authors independently assessed studies for inclusion, assessed trial quality and extracted the data using the agreed form.
Data were checked for accuracy. Evidence was assessed using the GRADE approach.
Main results
We included 15 trials (involving 1754 women) although our meta-analyses were based on fewer numbers of studies/women. All of the
included studies were undertaken in North America from 1982 to 2001. Two studies were low risk of bias in all domains, all other
studies had varying risk of bias. Four other studies were excluded and one study is ongoing.
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Eight comparisons were included in this review; three compared antibiotic (erythromycin, clindamycin, amoxicillin) versus placebo; five
compared an antibiotic versus another antibiotic (erythromycin, clindamycin, amoxicillin, azithromycin). No study reported different
antibiotic regimens.
Microbiological cure (primary outcome)
Antibiotics versus placebo: Erythromycin (average risk ratio (RR) 2.64, 95% confidence interval (CI) 1.60 to 4.38; two trials,
495 women; I2 = 68%; moderate-certainty evidence), and clindamycin (RR 4.08, 95% CI 2.35 to 7.08; one trial, 85 women;low-
certainty evidence) were associated with improved microbiological cure compared to a placebo control. In one very small trial comparing
amoxicillin and placebo, the results were unclear, but the evidence was graded very low (RR 2.00, 95% CI 0.59 to 6.79; 15 women).
One antibiotic versus another antibiotic: Amoxicillin made little or no difference in microbiological cure in comparison to ery-
thromycin (RR 0.97, 95% CI 0.93 to 1.01; four trials, 466 women; high-certainty evidence), probably no difference compared to
clindamycin (RR 0.96, 95% CI 0.89 to 1.04; one trial, 101 women; moderate-quality evidence), and evidence is very low certainty
when compared to azithromycin so the effect is not certain (RR 0.89, 95% CI 0.71 to 1.12; two trials, 144 women; very low-certainty
evidence). Azithromycin versus erythromycin (average RR 1.11, 95% CI 1.00 to 1.23; six trials, 374 women; I2 = 53%; moderate-
certainty evidence) probably have similar efficacy though results appear to favour azithromycin. Clindamycin versus erythromycin (RR
1.06, 95% CI 0.97 to 1.15; two trials, 173 women; low-certainty evidence) may have similar numbers of women with a microbiological
cure between groups.
Evidence was downgraded for design limitations, inconsistency, and imprecision in effect estimates.
Side effects of the treatment (maternal) (secondary outcome)
Antibiotics versus placebo: side effects including nausea, vomiting, and abdominal pain, were reported in two studies (495 women) but
there was no clear evidence whether erythromycin was associated with more side effects than placebo and a high level of heterogeneity (I
2 = 78%) was observed (average RR 2.93, 95% CI 0.36 to 23.76). There was no clear difference in the number of women experiencing
side effects when clindamycin was compared to placebo in one small study (5/41 versus 1/44) (RR 6.35, 95% CI 0.38 to 107.45, 62
women). The side effects reported were mostly gastrointestinal and also included resolving skin rashes.
One antibiotic versus another antibiotic: There was no clear difference in incidence of side effects (including nausea, vomiting,
diarrhoea and abdominal pain) when amoxicillin was compared to azithromycin based on data from one small study (36 women) (RR
0.56, 95% CI 0.24 to 1.31).
However, amoxicillin was associated with fewer side effects compared to erythromycin with data from four trials (513 women) (RR
0.31, 95% CI 0.21 to 0.46; I2 = 27%). Side effects included nausea, vomiting, diarrhoea, abdominal cramping, rash, and allergic
reaction.
Both azithromycin (RR 0.24, 95% CI 0.17 to 0.34; six trials, 374 women) and clindamycin (RR 0.44, 95% CI 0.22 to 0.87; two
trials, 183 women) were associated with a lower incidence of side effects compared to erythromycin. These side effects included nausea,
vomiting, diarrhoea and abdominal cramping.
One small study (101 women) reported there was no clear difference in the number of women with side effects when amoxicillin was
compared with clindamycin (RR 0.57, 95% CI 0.14 to 2.26; 107 women). The side effects reported included rash and gastrointestinal
complaints.
Other secondary outcomes
Single trials reported data on repeated infections, preterm birth, preterm rupture of membranes, perinatal mortality and low birthweight
and found no clear differences between treatments.
Many of this review’s secondary outcomes were not reported in the included studies.
Authors’ conclusions
Treatmentwith antibacterial agents achievesmicrobiological cure fromC.trachomatis infection during pregnancy. There was no apparent
difference between assessed agents (amoxicillin, erythromycin, clindamycin, azithromycin) in terms of efficacy (microbiological cure
and repeat infection) and pregnancy complications (preterm birth, preterm rupture of membranes, low birthweight). Azithromycin
and clindamycin appear to result in fewer side effects than erythromycin.
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All of the studies in this review were conducted in North America, which may limit the generalisability of the results. In addition, study
populations may differ in low-resource settings and these results are therefore only applicable to well-resourced settings. Furthermore,
the trials in this review mainly took place in the nineties and early 2000’s and antibiotic resistance may have changed since then.
Further well-designed studies, with appropriate sample sizes and set in a variety of settings, are required to further evaluate interventions
for treating C.trachomatis infection in pregnancy and determine which agents achieve the best microbiological cure with the least side
effects. Such studies could report on the outcomes listed in this review.
P L A I N L A N G U A G E S U M M A R Y
Treatment of genital Chlamydia trachomatis infection in pregnancy
What is the issue?
This review aimed to assess whether the treatment of chlamydial infection during pregnancy cured the infection and prevented
complications to the women and babies without causing side effects. This new review supersedes an earlier review on this topic.
Why is this important?
Chlamydia trachomatis is a bacterial infection which is sexually transmitted. It is more common in younger women. Women may
have the infection without knowing it. In pregnant women, genital Chlamydia trachomatis can cause pregnancy complications such as
preterm labour, preterm birth, premature rupture of the membranes, low birthweight of infants, and infection in the uterus after giving
birth. Babies who acquire Chlamydia trachomatis during birth can develop infection of the lungs and the eyes.
Finding an effective treatment with minimal side effects is extremely important considering the complications that can occur with
untreated Chlamydia trachomatis infection in pregnancy.
What evidence did we find?
We searched for evidence (June 2017) and included 15 studies in the review. The studies had a mixed risk of bias and were of limited
quality, often with small numbers of participants. Three studies compared antibiotics (erythromycin, clindamycin, and amoxicillin)
with placebo. The other studies compared different antibiotics with each other.
All of the studies reported on curing chlamydia, based on the elimination of the bacteria, with an antibiotic. Erythromycin (moderate-
quality evidence from two studies, 495 women) and clindamycin (low-quality evidence from one study, 85 women) appeared to be
more effective than placebo. The quality of the evidence for amoxicillin versus placebo (one study 15 women) was very low so we
cannot be certain of the results.
When comparing different antibiotics with each other, no one antibiotic was substantially better than another at curing chlamydia in the
studies that we examined: amoxicillin versus azithromycin (very low-quality evidence from two studies, 144 women), amoxicillin versus
erythromycin (high-quality evidence from four studies, 466 women), azithromycin versus erythromycin (moderate-quality evidence
from six studies, 374 women), clindamycin versus erythromycin (low-quality evidence from two studies, 173 women), amoxicillin
versus clindamycin (moderate-quality evidence from one study, 101 women). Only single trials assessed repeated infections, preterm
birth, preterm rupture of membranes, perinatal mortality and low birthweight and found there were no clear differences between the
different types of antibiotics examined.
Side effects were more common with erythromycin (two studies, 495 women) and clindamycin (one study, 85 women) than with
placebo. Amoxicillin resulted in fewer side effects than azithromycin (one study, 36 women) or erythromycin (four studies, 513 women),
and azithromycin caused fewer side effects than erythromycin (six studies, 374 women). Amoxicillin and clindamycin produced a
similar number of side effects in one study (107 women).
What does this mean?
Treatment of chlamydia infection with antibiotics appears to be effective during pregnancy. There is no clear difference between
amoxicillin, erythromycin, clindamycin, azithromycin in curing the infection or preterm birth, preterm rupture of membranes, and
low birthweight. Azithromycin and clindamycin appear to result in fewer side effects than erythromycin.
The included studies were all carried out in North America. Chlamydia testing remains a problem in low-resource settings because of
its costs. We conclude that well-designed studies of appropriate sample size, in different settings, are needed to further assess the effects
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of treatment of chlamydia infection in pregnancy. Resistance to the tested antibiotics could have changed since the studies included
in this review were conducted. In particular, future research could report on the outcomes of focus in this review and target those
antibiotics, such as amoxicillin and clindamycin, which may be effective in curing chlamydia with the least side effects.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Erythromycin compared to placebo for treating genital Chlamydia trachomatis infection in pregnancy
Patient or population: Pregnant women with a conf irmed Chlamydia trachomatis infect ion
Setting: Obstetric Clinics, USA
Intervention: Erythromycin
Comparison: Placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with Erythromycin
Microbiological cure Study populat ion Average RR 2.64
(1.60 to 4.38)
495
(2 RCTs)
⊕⊕⊕©
MODERATE 12
344 per 1000 908 per 1000
(550 to 1000)
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Stat ist ical Heterogeneity (I2 > 60%). (Inconsistency: -1)
2 One included study has design lim itat ions but contributed < 40%weight. (Not downgraded)
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B A C K G R O U N D
The prevalence of chlamydial infection in pregnancy is between
2% to 30% depending on the patient’s age and risk factors
(Berggren 2011;Much 1991). It is particularly common inwomen
younger than 25 years of age (Walker 2012). Genital Chlamydia
trachomatis (C.trachomatis) infection has been shown to be asso-
ciated with pregnancy complications such as miscarriage (Nigro
2011), preterm labour (Pararas 2006; Rours 2011), low birth-
weight (Attenburrow 1985) and increased perinatal mortality
(Silva 2011). There may also be an association with preterm
rupture of membranes (Blas 2007) and postpartum endometritis
(Ismail 1987). If the mother is untreated, 20% to 50% of new-
born babies may develop chlamydial conjunctivitis (Kakar 2010),
and another 10% to 20% may develop C.trachomatis pneumonia
(Rours 2009). Vaginal birth is associated with the highest risk of
transmission of chlamydial infection, however, there is a small risk
of acquiring the infection even in infants born by caesarean sec-
tion with premature rupture of membranes and intact membranes
(Pammi 2012; Yu 2009).
GenitalC.trachomatis infection is detected by nucleic acid amplifi-
cation test (NAAT) on the specimens of genital secretions or urine.
This test has replaced tissue culture of C.trachomatis (Jespersen
2005).
Description of the condition
Genital C.trachomatis infection is a common bacterial sexually
transmitted infection. The majority of women infected with this
bacteria are asymptomatic and, therefore, may be more likely to
transmit the infection because they do not seek treatment for the
infection, which may result in a longer duration of the infection.
The sequelae of C.trachomatis genital infection range from cervici-
tis to pelvic inflammatory disease, perihepatitis, ectopic pregnancy
and infertility (Zenilman 2012).We have described complications
of pregnancy and diseases of newborn related to genital Chlamy-
dia infection in the Background section above.
C.trachomatis is a small gram-negative intracellular bacteriumwith
a two-phased life-cycle, which includes the form that infects new
cells, (e.g. the small elementary body) and the active form (e.g.
the reticulate body). The life-cycle is about two to three days,
and, therefore, sustained high serum minimum inhibitory con-
centration of antimicrobial agents is needed to achieve eradica-
tion of the infection, which can be achieved by long-acting an-
timicrobials treatment or prolonged treatment. The incubation
period of C.trachomatis infection varies between seven and 14 days
(Zenilman 2012).
Description of the intervention
There are various treatment regimens for the management of
chlamydial infection during pregnancy, however, there is no con-
sensus on the most effective and safest option. In some, the hosts’
immune system may even clear the infection.
According to the Centers for Disease Control and Prevention
(CDC) guideline followed by many countries around the world,
the recommended regimens for treatment of genital chlamydial
infection in pregnancy are azithromycin (1 g orally given as a sin-
gle dose) or amoxicillin (500 mg orally three times daily for seven
days) (Workowski 2010). The alternative regimen according to
the CDC guideline is erythromycin (500 mg or 250 mg orally
four times daily for seven days), or erythromycin ethylsuccinate
(800 mg orally four times daily for seven days, or 400 mg orally
four times daily for 14 days) (Workowski 2010). Erythromycin is
associated with a high degree of gastrointestinal side effects (pri-
marily nausea) and the compliance may be an issue in such cases
(Workowski 2010).
Women who present in labour but were not treated for a prior
positive chlamydial test are advised to be treated immediately with
one of the above regimens.However, such late treatment is unlikely
to substantially decrease the risk of transmission of Chlamydia to
the newborn.
Clindamycin is another alternative drug for treatment of genital
C.trachomatis infection. Despite it being safe in pregnancy, clin-
damycin is not used widely due to its cost (Miller 2000).
Other antibiotics such as doxycycline, levofloxacin, ofloxacin,
and erythromycin estolate are used for the treatment of genital
C.trachomatis outside of pregnancy. These drugs are contraindi-
cated in pregnancy and lactation (Workowski 2010).
Azithromycin is believed to be the superior agent in comparison
to other antibiotics for treatment of chlamydial infection but new
research has emerged suggesting that there is a higher failure rate
with azithromycin treatment of chlamydial infection than previ-
ously believed (Schwebke 2011). One of the explanations for this
recent finding is a higher sensitivity ofNAAT in comparison to that
previously used in the tissue culture as a test of cure (Handsfield
2011), although it does not explain the similar cure rates reported
after doxycycline treatment with both of these tests. Another ex-
planation for treatment failure is heterotopic resistance with high
Chlamydia loads which leads to treatment failures (Horner 2006).
Re-infection is also a cause of treatment failure (Horner 2006).
Cure rates of C.trachomatis in women who are pregnant are lower
than in non-pregnant women. The reasons behind this is a gen-
erally higher failure rate of treatment with amoxicillin, which has
been traditionally used for treatment of C.trachomatis infection
during pregnancy. A test of cure has always been recommended for
all pregnant women and is performed no earlier than three weeks
after treatment is initiated (Workowski 2010).
The previousCochrane reviewon interventions for treating genital
C.trachomatis infection in pregnancy found that amoxicillin was as
effective as erythromycin (odds ratio (OR) 0.54, 95% confidence
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interval (CI) 0.28 to 1.02) (Brocklehurst 1998). Amoxycillin was
found to be better tolerated than erythromycin (OR 0.16, 95%
CI 0.09 to 0.30). Clindamycin and azithromycin were reported
to be effective, however, the numbers of women included in trials
were small (Brocklehurst 1998). New studies have been published
in this area, therefore, it is important to update this review, which
was done under new authorship.
How the intervention might work
Irradicating genital chlamydial infection during pregnancy with
antibacterial drugs may lead to the following:
• treatment of symptoms and sequelae of genital chlamydial
infection such as discharge, cervicitis, pelvic inflammatory
disease, tubal disease and infertility;
• a decrease in perinatal complications such as preterm labour
and early pregnancy loss, preterm rupture of membranes;
• a decrease in transmission of the infection to the fetus or
newborn and, therefore, prevention of intrauterine infection,
neonatal conjunctivitis and pneumonia during pregnancy;
• prevention of postpartum infection such as endometritis.
Why it is important to do this review
It is important to assess the different interventions for treating
genital C.trachomatis in order to establish whether effective treat-
ment of this infection improves perinatal outcomes and decreases
maternal complications. This new review updates and replaces an
earlier Cochrane review on this topic (Brocklehurst 1998).
O B J E C T I V E S
To establish the most efficacious and best-tolerated therapy for
treatment of genital chlamydial infection in preventing maternal
infection and adverse neonatal outcomes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials. Cluster-randomised tri-
als will be eligible for inclusion in this review in the future up-
dates if identified. Quasi-randomised trials and trials using cross-
over design were not eligible for inclusion. We included studies
published in abstract form.
Types of participants
Pregnant women with a confirmed C.trachomatis infection.
Types of interventions
• Any antibiotic versus no treatment or placebo for genital
C.trachomatiss infection in pregnancy
• One antibiotic versus another antibiotic
• Different antibacterial regimens
Types of outcome measures
Primary outcomes
• Microbiological cure - negative Chlamydia test at least three
weeks after treatment of the mother
Secondary outcomes
A. Maternal
• Repeated infection
• Preterm labour
• Preterm birth
• Preterm rupture of membranes
• Chorioamnionitis
• Postpartum endometritis
• Sepsis
• Prolonged hospital stay of the mother
• Side effects of treatment
• Maternal satisfaction with treatment
B. Fetal/neonatal
• Perinatal mortality
• Neonatal conjunctivitis
• Neonatal pneumonia
• Fetal anomalies
• Low birthweight
• Apgar score less than seven at five minutes
C. Cost
• Cost of treatment
Search methods for identification of studies
Themethods section of this review is based on a standard template
used by the Cochrane Pregnancy and Childbirth Group.
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Electronic searches
We searched the Cochrane Pregnancy and Childbirth Group’s Tri-
als Register by contacting their Information Specialist (26 June
2017).
The Register is a database containing over 23,000 reports of con-
trolled trials in the field of pregnancy and childbirth. For full
search methods used to populate the Pregnancy and Childbirth
Group’s Trials Register including the detailed search strategies for
CENTRAL, MEDLINE, Embase and CINAHL, the list of hand-
searched journals and conference proceedings, and the list of jour-
nals reviewed via the current awareness service, please follow this
link to the editorial information about the Cochrane Pregnancy
and Childbirth Group in the Cochrane Library and select the
‘Specialized Register ’ section from the options on the left side of
the screen.
Briefly, the Cochrane Pregnancy and Childbirth’s Trials Register
is maintained by their Information Specialist and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major
conferences;
6. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Search results are screened by two people and the full text of all
relevant trial reports identified through the searching activities de-
scribed above is reviewed. Based on the intervention described,
each trial report is assigned a number that corresponds to a spe-
cific Pregnancy and Childbirth review topic (or topics), and is
then added to the Register. The Information Specialist searches the
Register for each review using this topic number rather than key-
words. This results in a more specific search set that has been fully
accounted for in the relevant review sections (Included studies;
Excluded studies; Ongoing studies)
In addition, we searched ClinicalTrials.gov and the WHO Inter-
national Clinical Trials Registry Platform (ICTRP) (26 June 2017)
for unpublished, planned and ongoing trial reports. The search
terms we used are given in Appendix 1.
Searching other resources
We searched the reference lists of retrieved studies.
We did not apply any language or date restrictions.
Data collection and analysis
Themethods section of this review is based on a standard template
used by the Cochrane Pregnancy and Childbirth Group.
Selection of studies
Two review authors independently assessed all the potential studies
identified as a result of the search strategy for inclusion. Two review
authors assessed the quality and extracted the data using the agreed
form. Discrepancies were resolved through discussion with a third
review author when needed.We entered data intoReviewManager
software and checked for accuracy. When information regarding
any of the above was unclear, we attempted to contact authors of
the original reports to provide further details.
Studies published only in abstract form were included if they oth-
erwise satisfied inclusion criteria. The authors of such studies were
contacted if any additional information was required.
Data extraction and management
We designed a form to extract data. For eligible studies, review
authors extracted the data using the agreed form. We resolved
discrepancies through discussion or, if required, we consulted a
third assessor. We entered data into Review Manager software (
RevMan 2014), and checked for accuracy.
When information regarding any of the above is unclear, we at-
tempted to contact authors of the original reports to provide fur-
ther details.
Assessment of risk of bias in included studies
Review authors independently assessed risk of bias for each study
using the criteria outlined in theCochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011). We resolved any disagree-
ment by discussion or by involving a third assessor.
(1) Random sequence generation (checking for possible
selection bias)
We described for each included study the method used to generate
the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups.
We assessed the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
We described for each included study the method used to con-
ceal allocation to interventions prior to assignment and assessed
whether intervention allocation could have been foreseen in ad-
vance of, or during recruitment, or changed after assignment.
We assessed the methods as:
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• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We described for each included study the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. We considered that studies
were at low risk of bias if they were blinded, or if we judged that
the lack of blinding would be unlikely to affect results.We assessed
blinding separately for different outcomes or classes of outcomes.
We assessed the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We described for each included study the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received. We assessed blinding separately for different
outcomes or classes of outcomes.
We assessed methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We described for each included study, and for each outcome or
class of outcomes, the completeness of data including attrition and
exclusions from the analysis. We stated whether attrition and ex-
clusions were reported and the numbers included in the analysis at
each stage (compared with the total randomised participants), rea-
sons for attrition or exclusion where reported, and whether miss-
ing data were balanced across groups or were related to outcomes.
Where sufficient information was reported, or could be supplied
by the trial authors, we re-included missing data in the analyses
which we undertook.
We assessed methods as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomisation);
• unclear risk of bias.
A cut-off point of 20% was used to assess the level of missing data
as adequate for different outcomes.
(5) Selective reporting (checking for reporting bias)
We described for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• low risk of bias (where it is clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review have been reported);
• high risk of bias (where not all the study’s pre-specified
outcomes have been reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)
We described for each included study any important concerns we
have about other possible sources of bias.
We assessed whether each study was free of other problems that
could put it at risk of bias:
• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of other bias.
(7) Overall risk of bias
We made explicit judgements about whether studies were at high
risk of bias, according to the criteria given in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011). With
reference to (1) to (6) above, we assessed the likely magnitude and
direction of the bias and whether we considered it was likely to
impact on the findings. We explored the impact of the level of bias
through undertaking sensitivity analyses - see Sensitivity analysis.
Assessment of the quality of the evidence using the
GRADE approach
For this update , we assessed the quality of the evidence for all com-
parisons using the GRADE approach as outlined in the GRADE
handbook in order to assess the quality of the body of evidence
relating to the main outcome of microbiological cure.
We used GRADEpro GDT to import data from ReviewManager
5.3 (RevMan 2014) to create ’Summary of findings’ tables. A sum-
mary of the intervention effect and a measure of quality for each
of the outcomes was produced using the GRADE approach. The
GRADE approach uses five considerations (study limitations, con-
sistency of effect, imprecision, indirectness and publication bias)
to assess the quality of the body of evidence for each outcome. The
evidence can be downgraded from ’high quality’ by one level for
serious (or by two levels for very serious) limitations, depending
on assessments for risk of bias, indirectness of evidence, serious
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inconsistency, imprecision of effect estimates or potential publi-
cation bias.
Measures of treatment effect
Dichotomous data
For dichotomous data, we presented results as summary risk ratio
with 95% confidence intervals.
Continuous data
For continuous data, we planned to use the mean difference if
outcomesweremeasured in the sameway between trials.Wewould
have used the standardised mean difference to combine trials that
measured the same outcome, but used different methods.
Unit of analysis issues
Cluster-randomised trials
We did not identify any cluster-randomised trials for inclusion in
this version of the review. If we identify any cluster-randomised
trials for inclusion in future updates, we will include them in our
analyses along with individually-randomised trials. We will adjust
their standard errors using the methods described in the Cochrane
Handbook for Systematic Reviews of Interventions using an estimate
of the intra-cluster correlation co-efficient (ICC) derived from the
trial (if possible), from a similar trial or from a study of a similar
population. If we use ICCs from other sources, we will report
this and conduct sensitivity analyses to investigate the effect of
variation in the ICC. If we identify both cluster-randomised trials
and individually-randomised trials, we will synthesise the relevant
information. We will consider it reasonable to combine the results
from both if there is little heterogeneity between the studies and
the interaction between the effect of intervention and the choice
of randomisation unit is considered to be unlikely.
We will acknowledged heterogeneity in the randomisation unit
and perform a subgroup analysis to investigate the effects of the
randomisation unit.
Cross-over trials
This study design is not eligible for inclusion in this review.
Other unit of analysis issues
We identified the trials with more than two treatment groups and
included each pair-wise comparison separately, but with shared
intervention groups divided out approximately evenly among the
comparisons. For dichotomous outcomes, both the number of
events and the total number of patients were divided up. For con-
tinuous outcomes, only the total number of participants were di-
vided up and the means and standard deviations left unchanged
(Cochrane Handbook for Systematic Reviews of Interventions 16.5.4).
Dealing with missing data
For included studies, we noted levels of attrition. We planned to
explore the impact of including studies with high levels of missing
data in the overall assessment of treatment effect by using sensi-
tivity analysis (see Sensitivity analysis).
For all outcomes, we carried out analyses, as far as possible, on
an intention-to-treat basis, i.e. we attempted to include all partic-
ipants randomised to each group in the analyses, and all partici-
pants were analysed in the group to which they were allocated, re-
gardless of whether or not they received the allocated intervention.
The denominator for each outcome in each trial was the number
randomised minus any participants whose outcomes were known
to be missing.
We would have excluded studies with more than 20% missing
data.
Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using
the T², I² and Chi² statistics. We regarded heterogeneity as sub-
stantial if the I² was greater than 30% and either the T² was greater
than zero, or there was a low P value (less than 0.10) in the Chi²
test for heterogeneity.
Assessment of reporting biases
In future updates of this review, if there are 10 or more studies
in the meta-analysis, we will investigate reporting biases (such as
publication bias) using funnel plots and will assess funnel plot
asymmetry visually. If asymmetry is suggested by a visual assess-
ment, we will perform exploratory analyses to investigate it.
Data synthesis
We carried out statistical analysis using the Review Manager soft-
ware (RevMan 2014).We used fixed-effect meta-analysis for com-
bining data where it was reasonable to assume that studies were
estimating the same underlying treatment effect: i.e. where trials
were examining the same intervention, and the trials’ populations
and methods were judged sufficiently similar. If there was clinical
heterogeneity sufficient to expect that the underlying treatment ef-
fects differed between trials, or if substantial statistical heterogene-
ity was detected, we used random-effects meta-analysis to produce
an overall summary, if an average treatment effect across trials was
considered clinically meaningful. The random-effects summary
was treated as the average range of possible treatment effects and
we discussed the clinical implications of treatment effects differing
10Interventions for treating genital Chlamydia trachomatis infection in pregnancy (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
between trials. If the average treatment effect was not clinically
meaningful, we did not combine trials.
Where we used random-effects analyses, the results are presented
as the average treatment effect with 95% confidence intervals, and
the estimates of T² and I².
Subgroup analysis and investigation of heterogeneity
We did not carry out ant of the planned subgroup analyses as the
outcomes only had a few included trials. In future updates if we
identify substantial heterogeneity, we will investigate it using sub-
group analyses and sensitivity analyses. We will consider whether
an overall summary is meaningful, and if it is, use random-effects
analysis to produce it.
We would consider carrying out the following subgroup analyses.
• Women with a first episode versus women with recurrent
(previously treated in pregnancy) genital C.trachomatis infection
• Women in the first half (before 20 weeks) versus women in
the second half (including 20 weeks and after 20 weeks) of
pregnancy
The following outcome would be used in subgroup analysis.
• Microbiological cure negative Chlamydia test after
treatment for the mother
We would have assessed subgroup differences by interaction tests
available within RevMan (RevMan 2014). We would have re-
ported the results of subgroup analyses quoting the Chi² statistic
and P value, and the interaction test I² value.
Sensitivity analysis
Sensitivity analyses were not performed as there were no aspects of
the review that may have affected the results, for example, the risk
of bias associated with the quality of some of the included trials.
We would have undertaken analysis of the primary outcome sepa-
rately for trials with low risk of bias and high and unknown risk of
bias (allocation concealment) if needed. Sensitivity analysis would
have been carried out to explore the effects of random-effects anal-
yses for outcomes with statistical heterogeneity. We would also
have carried out sensitivity analysis to investigate the effect of the
randomisation unit if we had included cluster-randomised con-
trolled trials along with the individually-randomised trials.
R E S U L T S
Description of studies
Results of the search
The search of the Cochrane Pregnancy and Childbirth Group’s
Trials Register retrieved 23 reports of 20 trials and we retrieved no
other studies from other sources (see: Figure 1). We included 15
studies, excluded four, and one is ongoing (Okunola 2013).
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Figure 1. Study flow diagram.
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Included studies
We included 15 studies into the meta-analysis with a total of 1754
women. Meta-analyses were mostly based on fewer numbers of
studies.
Methods
All the trials were randomised control trials of pregnant women
with confirmed Chlamydia trachomatis (C.trachomatis) infection.
Populations and settings
All of the included studies were undertaken in North America (14
in USA and one in Canada). One study took place in 1982, and
the rest took place in the nineties and early 2000s.
Interventions and comparisons
Two studies compared erythromycin and placebo (Alger 1991;
Martin 1997). One study compared clindamycin and placebo
(Alger 1991). One study compared amoxicillin versus placebo
(Bell 1982). Two studies compared azithromycin and amoxicillin
(Jacobson 2001; Kacmar 2001). Four studies compared amox-
icillin and erythromycin (Alary 1994; Magat 1993; Silverman
1994; Turrentine 1995). Six studies compared erythromycin and
azithromycin (Adair 1998; Bush 1994; Edwards 1996; Gunter
1996; Rosenn 1995; Wehbeh 1998). Two studies compared clin-
damycin and erythromycin (Alger 1991; Turrentine 1995). One
study compared amoxicillin and clindamycin (Turrentine 1995).
Funding sources
Adair 1998, Edwards 1996, and Turrentine 1995 had drugs do-
nated by a pharmaceutical company at no cost. Alger 1991 was
funded by a grant from the Upjohn company.
Alary 1994 was funded by a grant from the National Health Re-
search and Development Program. Kacmar 2001 was funded by
a NIH grant. Martin 1997 was funded by a National Institute
of Child Health and Human Development grant. Bell 1982 was
supported by a US Public Health Service grant.
Wehbeh 1998 was funded by local departmental funds.
Bush 1994, Gunter 1996, Jacobson 2001, Magat 1993, Rosenn
1995, and Silverman 1994 did not disclose any funding sources.
Trial authors’ declarations of interest
Declarations of interest were not mentioned in any of the included
studies.
Excluded studies
Reasons for exclusion are as follows.
• El-Shourbagy 2011 - this study examines the rate of pre-
eclampsia in groups of treated and non-treated Chlamydia
pneumoniae infections in pregnancy.
• McGregor 1990 - this study included pregnant women
with various genital tract infections and not only Chlamydia
trachomatis. The data for Chlamydia trachomatis infection were
not presented separately.
• Nadafi 2005 - this study included women with positive and
negative Chlamydia test, it was a cohort study, sequence
generation was not clear. The data for women with positive and
negative Chlamydia test are presented together.
• Zulkarneev 1998 - this study was not a randomised
controlled trial.
Risk of bias in included studies
See Figure 2 and Figure 3.
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Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Eleven studies had low risk of selection bias, e.g. three studies used
number of blocks for allocation (Adair 1998; Alary 1994; Rosenn
1995), four studies used computer-generated randomisation for
allocation (Bush 1994; Jacobson 2001; Martin 1997; Turrentine
1995), four studies used random number tables (Edwards 1996;
Kacmar 2001; Magat 1993; Silverman 1994). Four studies had
unclear risk of selection bias, e.g. allocation method was not de-
scribed (Alger 1991; Bell 1982; Gunter 1996; Wehbeh 1998).
Nine studies had a low risk of bias for allocation sequence. Six used
sealed opaque envelopes (Adair 1998; Bush 1994; Jacobson 2001,
Kacmar 2001; Rosenn 1995; Silverman 1994). One study used
identical treatment packs (Alary 1994). In two trials the medica-
tions were dispensed by the pharmacy to prevent the healthcare
practitioners knowing which medication and which dose were al-
located (Magat 1993; Turrentine 1995). There was an unclear risk
in six studies as allocation concealment was not described (Alger
1991; Bell 1982; Edwards 1996; Gunter 1996; Martin 1997;
Wehbeh 1998).
Blinding
Performance bias
Blinding of participants and personnel was performed four studies
(Alary 1994; Alger 1991; Martin 1997; Turrentine 1995).
Five studies did not implement blinding of participants or per-
sonnel and were assessed as high risk (Adair 1998; Edwards 1996;
Jacobson 2001; Magat 1993; Wehbeh 1998).
Six studies did not describe performance blinding (Bell 1982;
Bush 1994; Gunter 1996; Kacmar 2001; Rosenn 1995; Silverman
1994).
Assessment bias
Blinding of outcome assessment was unclear in 13 studies (Adair
1998; Alger 1991; Bell 1982; Bush 1994; Edwards 1996; Gunter
1996; Jacobson 2001; Kacmar 2001; Magat 1993; Martin 1997;
Rosenn 1995; Silverman 1994; Wehbeh 1998).
Assessment bias was assessed as low risk in two studies were staff
taking cultures were blinded to treatment group (Alary 1994;
Turrentine 1995).
Incomplete outcome data
No studies had significant attrition bias. All losses to follow-up
were described. One study (Bell 1982) had high attrition for the
final outcome reporting data for only 71% of participants. Five
studies are at unclear risk of attrition bias due to insufficient infor-
mation given in the study report (Gunter 1996), and some unex-
plained loss to follow-up (Jacobson 2001; Kacmar 2001; Martin
1997; Silverman 1994).
Selective reporting
One study was published only in abstract form and states that it
is an ongoing trial but no further information has been published
(Gunter 1996). The remaining 14 studies were rated as being at
low risk of reporting bias.
Other potential sources of bias
Two studies had unexplained different mean gestational ages in
women in the two treatment arms (Edwards 1996; Magat 1993).
The remaining 13 studies were assessed as being at a low risk of
other bias.
Effects of interventions
See: Summary of findings for the main comparison
Erythromycin compared to placebo for treating genital Chlamydia
trachomatis infection in pregnancy; Summary of findings 2
Clindamycin compared to placebo for treating genital Chlamydia
trachomatis infection in pregnancy; Summary of findings 3
Amoxicillin compared to placebo for treating genital Chlamydia
trachomatis infection in pregnancy; Summary of findings 4
Amoxicillin compared to azithromycin for treating genital
Chlamydia trachomatis infection in pregnancy; Summary of
findings 5 Amoxicillin compared to erythromycin for treating
genital Chlamydia trachomatis infection in pregnancy; Summary
offindings 6Azithromycin compared to erythromycin for treating
genital Chlamydia trachomatis infection in pregnancy; Summary
of findings 7Clindamycin compared to erythromycin for treating
genital Chlamydia trachomatis infection in pregnancy; Summary
of findings 8 Amoxicillin compared to clindamycin for treating
genital Chlamydia trachomatis infection in pregnancy
Erythromycin versus placebo (comparison 1)
Primary outcome
Microbiological cure
Erythromycin appears to improvemicrobiological cure in compar-
ison to placebo (moderate-certainty evidence, Summary of findings
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for the main comparison; (average risk ratio (RR) 2.64, 95% con-
fidence interval (CI) 1.60 to 4.38; 495 women; studies = two; I²
= 68%; Analysis 1.1)). There was evidence of substantial hetero-
geneity between the studies (I² = 68%) in effect size; both studies
found erythromycin improved microbiological cure.
Secondary outcomes
Preterm birth
There was no clear difference in preterm births (RR 0.90, 95%
CI 0.56 to 1.46; 405 women; studies = one; Analysis 1.2).
Preterm rupture of membranes
There was no clear difference in preterm rupture membranes be-
tween the treatment groups (RR 0.83, 95% CI 0.48 to 1.43; 389
women; studies = one; Analysis 1.3).
Side effects of treatment
We are uncertain if erythromycin results in a higher incidence of
side effects when compared to placebo (average RR 2.93, 95%
CI 0.36 to 23.76; 495 women; studies = two; I² = 78%; Analysis
1.4). There was substantial heterogeneity between the studies, I²
= 78%. The side effects reported included nausea, appetite loss
(Martin 1997), vomiting, diarrhoea, and abdominal pain (Alger
1991).
Perinatal mortality
There was no clear difference in perinatal deaths between the
groups (RR 3.01, 95% CI 0.32 to 28.74; 405 women; studies =
one; Analysis 1.5).
Low birthweight
There was no clear difference in low birthweight between the
groups (RR 0.77, 95% CI 0.42 to 1.40; 400 women; studies =
one; Analysis 1.6).
Other secondary outcomes
No studies assessed the other secondary outcomes.
Clindamycin versus placebo (comparison 2)
Primary outcome
Microbiological cure
Clindamycin appears to improvemicrobiological cure in compari-
son to placebo (low-certainty evidence, Summary of findings 2; (RR
4.08, 95% CI 2.35 to 7.08; 85 women; studies = one; Analysis
2.1)). One study (Alger 1991), which was funded by a pharma-
ceutical company contributed to this comparison.
Secondary outcomes
Side effects of treatment
There was no clear difference in side effects between the two
groups (RR 5.37, 95% CI 0.65 to 44.01; 85 women; studies =
one; Analysis 2.2). The side effects included a rash and mild gas-
trointestinal complaints including nausea and vomiting, abdomi-
nal pain, cramps and diarrhoea.
Other secondary outcomes
No studies assessed the other secondary outcomes.
Amoxicillin versus placebo (comparison 3)
Primary outcome
Microbiological cure
It is uncertain whether amoxicillin improves microbiological cure
in comparison to placebo but the certainty of this evidence is very
low (Summary of findings 3; (RR 2.00, 95% CI 0.59 to 6.79; 15
women; studies = one; Analysis 3.1)).
Secondary outcomes
No secondary outcomes were reported for this outcome in the
included studies.
Amoxicillin versus azithromycin (comparison 4)
Primary outcome
Microbiological cure
It is uncertain whether amoxicillin improves or reduces microbio-
logical cure in comparison to azithromycin because the certainty
of this evidence is very low (Summary of findings 4; (RR 0.89,
95% CI 0.71 to 1.12; 144 women; studies = two; Analysis 4.1)).
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Secondary outcomes
Repeated infection
There was no clear difference for the outcome of repeated infec-
tions between amoxicillin and azithromycin in the single included
study (RR 0.42, 95% CI 0.02 to 9.55; 34 women; studies = one;
Analysis 4.2).
Preterm birth
There was no clear difference in the incidence of preterm birth
between amoxicillin and azithromycin (RR 1.17, 95% CI 0.43 to
3.20; 90 women; studies = one; Analysis 4.3).
Side effects of treatment
Therewas no clear difference in side effects between the twogroups
(RR0.56, 95%CI 0.24 to 1.31; 36women; studies = one; Analysis
4.4). Side effects reported included nausea, vomiting, diarrhoea
and abdominal pain.
Other secondary outcomes
None were reported.
Amoxicillin versus erythromycin (comparison 5)
Primary outcome
Microbiological cure
Amoxicillin makes little or no difference to microbiological cure
in comparison to erythromycin (high-certainty evidence, Summary
of findings 5; (RR 0.97, 95%CI 0.93 to 1.01; 466 women; studies
= 4; Analysis 5.1)).
Secondary outcomes
Side effects of treatment
Amoxicillin was associated with reduced incidence of side effects
in comparison to erythromycin (RR 0.31, 95% CI 0.21 to 0.46;
513 women; studies = four; I² = 27%; Analysis 5.2). Side effects
associated with erythromycin use included nausea, vomiting, di-
arrhoea, abdominal cramping, rash, and an allergic reaction.
Other secondary outcomes
None were reported.
Azithromycin versus erythromycin (comparison 6)
Primary outcome
Microbiological cure
It appears that azithromycin probably improves microbiological
cure in comparison to erythromycin (moderate-certainty evidence,
Summary of findings 6; (average RR 1.11, 95% CI 1.00 to 1.23;
participants = 374; studies = six; I² = 53%; Analysis 6.1)), however,
there was substantial heterogeneity between the included studies
(I² = 53%) and the lower confidence interval just touches the line
of no effect.
Secondary outcomes
Repeated infection
There was no clear difference between azithromycin and amoxi-
cillin for the outcome of repeated infections (RR 1.37, 95% CI
0.32 to 5.73; 85 women; studies = one; Analysis 6.2).
Preterm birth
There was no clear difference in the rate of preterm birth between
azithromycin and amoxicillin (RR 0.77, 95% CI 0.29 to 2.10;
126 women; studies = one; Analysis 6.3).
Preterm rupture of membranes
There was no clear difference for the outcome of preterm rupture
of membranes between azithromycin and amoxicillin (RR 0.62,
95% CI 0.15 to 2.48; 126 women; studies = one; Analysis 6.4).
Side effects of treatment
Fewer women in the azithromycin group experienced side effects
in comparison to women receiving erythromycin (RR 0.24, 95%
CI 0.17 to 0.34; 374 women; studies = six; Analysis 6.5). These
side effects were mostly gastrointestinal in origin and included
nausea, vomiting, diarrhoea and abdominal cramping.
Other secondary outcomes
None were reported.
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Clindamycin versus erythromycin (comparison 7)
Primary outcome
Microbiological cure
Clindamycin may make little or no difference on microbiolog-
ical cure in comparison to erythromycin (low-certainty evidence,
Summary of findings 7; (RR 1.06, 95% CI 0.97 to 1.15; 173
women; studies = two; Analysis 7.1)).
Secondary outcomes
Side effects of treatment
Women in the clindamycin group experienced less side effects in
comparison to erythromycin (RR 0.44, 95% CI 0.22 to 0.87;
183 women; studies = two; Analysis 7.2). These side effects were
mostly gastrointestinal in origin and included nausea, vomiting,
diarrhoea and abdominal cramping.
Other secondary outcomes
None were reported.
Amoxicillin versus clindamycin (comparison 8)
Primary outcome
Microbiological cure
Amoxicillin probably makes little or no difference on microbio-
logical cure in comparison to clindamycin (moderate-certainty ev-
idence, Summary of findings 8; (RR 0.96, 95% CI 0.89 to 1.04;
101 women; studies = one; Analysis 8.1)).
Secondary outcomes
Side effects of treatment
There was no clear difference in number of side effects associated
with amoxicillin and clindamycin (RR 0.57, 95%CI 0.14 to 2.26;
107 women; studies = one; Analysis 8.2). The side effects reported
included rash and gastrointestinal complaints.
Other secondary outcomes
None were reported.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Clindamycin compared to placebo for treating genital Chlamydia trachomatis infection in pregnancy
Patient or population: Pregnant women with a conf irmed Chlamydia trachomatis infect ion
Setting: Obstetric Clinic, USA
Intervention: Clindamycin
Comparison: Placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with Clindamycin
Microbiological cure Study populat ion RR 4.08
(2.35 to 7.08)
85
(1 RCT)
⊕⊕©©
LOW 12
227 per 1000 927 per 1000
(534 to 1000)
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 The included study had design lim itat ion (Design lim itat ions: -1)
2 Wide conf idence interval and small sample size (Imprecision: -1)
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Amoxicillin compared to placebo for treating genital Chlamydia trachomatis infection in pregnancy
Patient or population: Pregnant women with a conf irmed Chlamydia trachomatis infect ion
Setting: USA
Intervention: Amoxicillin
Comparison: Placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with Amoxicillin
Microbiological cure Study populat ion RR 2.00
(0.59 to 6.79)
15
(1 RCT)
⊕©©©
VERY LOW 12
333 per 1000 667 per 1000
(197 to 1000)
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 The included study had design lim itat ion (Design lim itat ions: -1)
2 Wide conf idence intervals crossing the line of no ef fect, few events, and small sample size (Imprecision: -2)
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Amoxicillin compared to azithromycin for treating genital Chlamydia trachomatis infection in pregnancy
Patient or population: Pregnant women with a conf irmed Chlamydia trachomatis infect ion
Setting: Prenatal clinics, USA
Intervention: Amoxicillin
Comparison: Azithromycin
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with azithromycin Risk with Amoxicillin
Microbiological cure Study populat ion RR 0.89
(0.71 to 1.12)
144
(2 RCTs)
⊕©©©
VERY LOW 12
716 per 1000 637 per 1000
(509 to 802)
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 One study contribut ing to over 68% of weight to pooled analysis had some design lim itat ions (Design lim itat ions: -1)
2 Wide conf idence intervals crossing the line of no ef fect and small size (Imprecision: -2)
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Amoxicillin compared to erythromycin for treating genital Chlamydia trachomatis infection in pregnancy
Patient or population: Pregnant women with a conf irmed Chlamydia trachomatis infect ion
Setting: Obstetric centre or prenatal clinics in Canada, USA
Intervention: Amoxicillin
Comparison: Erythromycin
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with erythromycin Risk with Amoxicillin
Microbiological cure Study populat ion RR 0.97
(0.93 to 1.01)
466
(4 RCTs)
⊕⊕⊕⊕
HIGH
One study contribut ing
to 24% of weight had
some design lim itat ion.
(not downgraded)
954 per 1000 925 per 1000
(887 to 963)
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
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Azithromycin compared to erythromycin for treating genital Chlamydia trachomatis infection in pregnancy
Patient or population: Pregnant women with a conf irmed Chlamydia trachomatis infect ion
Setting: Prenatal clinics, and university medical centres, USA
Intervention: Azithromycin
Comparison: erythromycin
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with erythromycin Risk with Azithromycin
Microbiological cure Study populat ion Average RR 1.11
(1.00 to 1.23)
374
(6 RCTs)
⊕⊕⊕©
MODERATE 12
825 per 1000 916 per 1000
(825 to 1000)
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Most studies have design lim itat ions (Design lim itat ions: -1)
2 Stat ist ical heterogeneity at 53% (I2 < 60%) (not downgraded)
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Clindamycin compared to erythromycin for treating genital Chlamydia trachomatis infection in pregnancy
Patient or population: Pregnant women with a conf irmed Chlamydia trachomatis infect ion
Setting: Prenatal clinics, USA
Intervention: Clindamycin
Comparison: Erythromycin
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with erythromycin Risk with Clindamycin
Microbiological cure Study populat ion RR 1.06
(0.97 to 1.15)
173
(2 RCTs)
⊕⊕©©
LOW 12
905 per 1000 959 per 1000
(878 to 1000)
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 One study contribut ing to over 40% of weight to pooled analysis had some design lim itat ions (Design lim itat ions: -1)
2 Small sample size (Imprecision: -1)
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Amoxicillin compared to clindamycin for treating genital Chlamydia trachomatis infection in pregnancy
Patient or population: Pregnant women with a conf irmed Chlamydia trachomatis infect ion
Setting: Prenatal clinic, USA
Intervention: Amoxicillin
Comparison: Clindamycin
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with clindamycin Risk with Amoxicillin
Microbiological cure Study populat ion RR 0.96
(0.89 to 1.04)
101
(1 RCT)
⊕⊕⊕©
MODERATE 1
979 per 1000 940 per 1000
(871 to 1000)
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 The pooled ef fect was based on one study with a small sample size (Imprecision: -1)
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D I S C U S S I O N
Summary of main results
Fifteen studies involving 1754womenwere included in this review
but our meta-analyses are based on fewer numbers of studies/
women. We excluded four studies and one study is ongoing.
Erythromycin (moderate-certainty evidence) and clindamycin
(low-certainty evidence) were associated with a higher incidence
of microbiological cure in comparison to placebo. Results were
unclear in one very small study comparing amoxicillin placebo but
the evidence was graded very-low certainty.
There is no clear difference in microbiological cure between
the assessed agents compared to each other: amoxicillin ver-
sus azithromycin (very low-certainty evidence); amoxicillin ver-
sus erythromycin (high-certainty evidence); azithromycin versus
erythromycin (moderate-certainty evidence); clindamycin versus
erythromycin (low-certainty evidence); amoxicillin versus clin-
damycin (moderate-certainty evidence). There was no clear dif-
ference in repeat infections for amoxicillin versus azithromycin,
or azithromycin versus erythromycin. Most secondary outcomes
were not reported in any of the included studies.
Antibacterial treatment of genital Chlamydia trachomatis
(C.trachomatis) infection was associated with side effects which
were more common with the use of erythromycin and clin-
damycin than placebo as would be expected. Amoxicillin and clin-
damycin were associated with less side effects than azithromy-
cin and erythromycin. Azithromycin caused less side effects than
erythromycin. Side effects associated with erythromycin, azithro-
mycin and clindamycin included nausea, vomiting, abdominal
cramping and diarrhoea. Clindamycin use was occasionally asso-
ciated with a non severe rash.
Therewere only a few studies that assessed the outcomes of preterm
birth, preterm rupture of membranes and low birthweight. No
studies assessed chorioamnionitis, postpartum endometritis, sep-
sis, prolonged hospital stay, maternal satisfaction, neonatal con-
junctivitis, neonatal pneumonia, fetal anomalies, low birthweight
and Apgar scores.
Overall completeness and applicability of
evidence
All of the included studies were undertaken in North America (14
in USA and 1 in Canada) in 1982 and the mid to late nineties and
early 2000s. Antibiotic resistance may have changed since these
studies were performed. Study populations could differ in low-
resource settings and the results are therefore only applicable to
well-resourced settings. C.trachomatis testing remains a challenge
in low-resource settings because of the cost, and the treatment of
genital infection is still based on a syndromic approach (South
African STI guideline 2015). There was little or no information on
the outcomes of preterm labour, preterm birth, preterm rupture
of membranes, chorioamnionitis, postpartum endometritis, sep-
sis, prolonged hospital stay, maternal satisfaction with treatment,
perinatal mortality, neonatal conjunctivitis, neonatal pneumonia,
fetal anomalies, low birthweight, Apgar score less than seven at
five minutes and cost of treatment.
Quality of the evidence
We assessed the included studies for risk of bias. Two studies (Alary
1994; Turrentine 1995) were assessed to be at low risk of bias in all
domains. The remaining studies had varying risks of bias; blinding
of participants and outcome assessors was unclear, not reported,
or not attempted in most studies. We carried out formal assess-
ments of quality of the evidence using GRADEpro for the review’s
primary outcome of microbiological cure. For this outcome, the
evidence was graded from very low to high certainty for the differ-
ent comparisons: amoxicillin versus placebo and versus azithromy-
cin were graded very low quality; clindamycin versus placebo, and
versus erythromycin were graded low quality; erythromycin versus
placebo, azithromycin versus erythromycin, and amoxicillin ver-
sus clindamycin were graded moderate quality; amoxicillin versus
erythromycin was graded high quality. Evidence was downgraded
for limitations in study designs, inconsistency, and imprecision in
effect estimates.
Potential biases in the review process
Evidence in this review was derived from studies identified in a
detailed search process. Trials comparing interventions to treat C.
trachomatis infection in pregnancy that have not been published
may not have been identified. We attempted to minimise bias in
the review process by having two review authors independently
extract data.
Agreements and disagreements with other
studies or reviews
We did not find any publications which included meta-analysis
of published studies, but we have identified two recent reviews/
guidelines addressing the treatment of C.trachomatis during preg-
nancy.
CDC guidelines (CDC 2015) and the up-to-date review (
Marrazzo 2016) recommends the treatment of C.trachomatis in-
fection in pregnancy with azithromycin based on clinical practice
as it is safe and effective. Recommended alternatives suggested by
both documents are amoxicillin and erythromycin. A test of cure is
recommended in pregnant women three to four weeks after treat-
ment and again three months later. Resistance to amoxicillin is
highlighted, however, it is referenced with respect to animal stud-
ies only. The review and guideline did not suggest clindamycin as
27Interventions for treating genital Chlamydia trachomatis infection in pregnancy (Review)
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an alternative, but according to limited data from this review it
could be considered as a treatment option.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The current evidence on individual antibiotic interventions for
treating genital Chlamydia trachomatis (C.trachomatis) infection
in pregnancy is limited - the largest meta-analysis in this review
includes six studies involving 374 women, and most include only
one or two studies. Clindamycin, erythromycin, and amoxicillin
seem to be effective compared with placebo in achieving micro-
biological cure, however, the evidence related to amoxicillin is
very low quality and we cannot be certain of this. There were no
clear differences in microbiological cure between different antibi-
otics when compared against each other. Erythromycin was asso-
ciated with more side effects than clindamycin, azithromycin, and
amoxicillin, including nausea, vomiting, diarrhoea and abdominal
cramps. The evidence related to effects of treatment on a number
of maternal and most fetal outcomes is sparse.
Implications for research
Further well-designed studies of appropriate sample size are re-
quired to assess interventions for treating C.trachomatis infec-
tion in pregnancy with agents achieving the best microbiological
cure and causing least side effects such as amoxicillin and clin-
damycin. The secondary outcomes in this review have been under-
reported. Future research could assess these outcomes: repeated
infection, preterm labour, pretermbirth, preterm rupture of mem-
branes, chorioamnionitis, postpartum endometritis, sepsis, pro-
longed hospital stay of themother,maternal satisfactionwith treat-
ment, perinatal mortality, neonatal conjunctivitis, neonatal pneu-
monia, fetal anomalies, low birthweight, Apgar score less than
seven at five minutes and cost of treatment. A network meta-anal-
ysis would be beneficial to compare agents which have not yet
been compared directly. Future research is needed in low-resource
settings were population characteristics, cost, and treatment ap-
proach may differ from the studies included in this review.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Adair 1998
Methods Randomised controlled trial.
Participants 106 pregnant women screened positive by a direct DNA probe forChlamydia trachomatis
were enrolled. Exclusion criteria included hypersensitivity to erythromycin or azithro-
mycin, lack of desire to participate in the study, or gestational age at most 14 weeks. 85
women entered and completed the entire trial protocol. 42 were assigned to azithromycin
and 43 were assigned to erythromycin
Interventions Azithromycin 1 g oral slurry in a single dose or erythromycin base 500 mg orally 4 times
daily for 7 days
Outcomes Cure rate, repeated infection, side effects (nausea and vomiting)
Notes In the azithromycin group, 9 were lost to follow-up, 2 were not pregnant, 1 was treated
off protocol.
In the erythromycin group, 7 were lost to follow-up, 2 were not pregnant, 1 was treated
off protocol.
74.4% in the erythromycin group and 50% in the azithromycin group completed the
protocol as prescribed within the 3-week period. This high rate of prolonged, uncon-
firmed test of cure could have resulted in higher positive tests of cure or possibly higher
re-infection rates in the azithromycin group.
Compliance in the azithromycin group was 97.6% and in the erythromycin group it was
53.5%.
Patients with positive Chlamydia assays at the test of cure were treatedwith the alternative
agent to the originally assigned agent.
Sample size estimates suggested the need to enrol 120 patients
Performed at Bowman Gray School of Medicine of Wake Forest University, North Car-
olina, USA
Sources of trial funding: The drugs used in this study were supplied without charge by
Pfizer, Incorporated, New York, New York
Declarations of interest: Not reported.
Trial dates: 1995 - 1997.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Assignment to treatment was made by random numbers
in blocks of 20 by the program Rancode-Plus 3.1.1
Allocation concealment (selection bias) Low risk Allocation cardswere placed in a sealed opaque envelope.
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Adair 1998 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No attempt was made to blind the investigators to treat-
ment allocations after enrolment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 85 (80.2%) women completed the study. The number
lost to follow-up was similar in both the groups
Selective reporting (reporting bias) Low risk No selective reporting noted.
Other bias Low risk The study appears to be free of other sources of bias.
Alary 1994
Methods Randomised controlled trial.
Participants 210 women culture-positive for Chlamydia trachomatis were included.
Exclusion criteria: allergy to either drug, treatment with antibiotics after the chlamydial
culture was done, abortion or miscarriage, moving away from the study area or more
than 38 weeks of gestation at diagnosis
11 were excluded from the final analysis (see below).
Outcome data were available for 199 women. 100 were treated with amoxicillin
99 were treated with erythromycin.
Interventions Amoxycillin 500 mg 3 times daily for 7 days versus erythromycin 500 mg 4 times daily
for 7 days
Outcomes Cure rate.
SIde effects (gastrointestinal).
Notes Urethral samples from sexual partners of positive patients were cultured, and doxycycline
treatment (100 mg twice a day for 10 days) was given free of charge
Eye, nose, pharyngeal, rectal and genital swabs were obtained in infants in the week after
birth
Patients unable to tolerate their medication were offered the alternative treatment. In
these cases, second cervical and urethral samples were cultured and a doctor independent
of the study allocated the alternative treatment without informing the patients, investi-
gators or the responsible physicians what the first therapy had been
11 of the 210 enrolled women were excluded from the final analysis
6 (4 amoxicillin, 2 erythromycin) did not attend to any follow-up visits
1 (amoxicillin) received another antibiotic during the early phase of the trial
2 (erythromycin) delivered before any outcome measurements.
In 2 women receiving erythromycin, treatment was interrupted by the physician because
of side effects and the patients did not come for follow-up tests
In the erythromycin group, 5 patients had a temporary treatment interruption due to
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Alary 1994 (Continued)
severe side effects and 12 patients had to be stopped permanently
In the amoxicillin group, 1 had temporary treatment interruption and 1 permanent
withdrawal due to side effects
Of the 13 patients who could not complete their treatment, 10 accepted an alternative
treatment, and all but 1 were cured. Re-infection cannot be ruled out for this patient,
since her regular sexual partner did not attend follow-up
Compliance was above 95% in both groups with exclusion of the 13 patients who could
not complete their treatment because of side effects
Study performed in 9 obstetric centres in the province of Quebec, Canada
Sources of trial funding: Study was supported by a grant from the National Health
Research and Development Program
Declarations of interest: Not reported.
Trial dates: January 1990 - April 1993.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Each woman was randomly assigned treatment in a pre-
determined order in blocks of 10
Allocation concealment (selection bias) Low risk Identical treatment packs were used.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blinded. “The drugs were issued in identical
capsules in similar blister packs. In the amoxycillin packs,
to maintain double-blind nature of the project, the third
daily dose was a placebo whereas other capsules con-
tained 250 mg amoxycillin.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Staff taking sample cultures after treatment termination
were unaware of the treatment group assignment
Incomplete outcome data (attrition bias)
All outcomes
Low risk After randomisation, only 5.6% women lost to follow -
up, equally balanced across the two groups
Selective reporting (reporting bias) Low risk No selective reporting noted.
Other bias Low risk The study appears to be free of other sources of bias.
Alger 1991
Methods Randomised controlled trial.
Participants 135 pregnant women with culture-positive endocervical Chlamydia trachomatis infection
were enrolled. Data were available for 126.
40 women received erythromycin and a clindamycin placebo.
42 women received clindamycin and erythromycin placebo.
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Alger 1991 (Continued)
44 received a placebo for both clindamycin and erythromycin.
Interventions Clindamycin (450 mg), erythromycin (331 mg), placebo orally 4 times per day for 14
days
Outcomes Cure rate, side effects.
Notes Partners treated with doxycycline 100 mg orally twice a day for 7 days
9 participants were delivered at another hospital and were lost to follow-up
Study was performed at the University of Maryland Obstetric Clinic, Baltimore, USA
Sources of trial funding: Study was funded by a grant from the Upjohn company.
Declarations of interest: Not reported.
Trial dates: October 1985 - April 1998.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described.
Allocation concealment (selection bias) Unclear risk Not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blinded. “Medications were dispensed in blis-
ter packs with each dose packaged sequentially in an in-
dividual cell, permitting accurate determination of the
specific number and timing of missed doses.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk From table 3, it is clear that there was no missing data
in the placebo group while the missing outcome data
were balanced in numbers across the two interventions
groups
Selective reporting (reporting bias) Low risk No selective reporting noted.
Other bias Low risk The study appears to be free of other sources of bias.
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Bell 1982
Methods Randomised controlled trial.
Participants 21 gravidas beyond the 24th week of pregnancy with Chlamydial trachomatis infection
who were not allergic to penicillin. Only had outcomes for 15 participants
9 were in the amoxicillin group.
6 were in the placebo group.
Interventions Amoxicillin 500 mg 3 times a day (11 participants) or placebo (10 participants)
Outcomes Postpartum culture: 3/9 had positive culture in amoxicillin group. 4/6 had a positive
culture in the placebo group
Notes Amoxicillin group: 2 were lost to follow-up.
Placebo: 1 was treated elsewhere with erythromycin, 2 were lost to follow-up and 1 died
due to a cerebrovascular incident
Site of the studywas not stated but assumed to be performed atUniversity ofWashington,
Seattle, USA
Sources of trial funding: Study was supported by a US Public Health Service grant.
Declarations of interest: Not reported.
Trial dates: Not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described.
Allocation concealment (selection bias) Unclear risk Not described, unlikely.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described, unlikely.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described, unlikely.
Incomplete outcome data (attrition bias)
All outcomes
High risk All participants accounted for but only 15/21 were as-
sessed for final outcome (71%)
Selective reporting (reporting bias) Low risk No selective reporting noted.
Other bias Low risk The study appears to be free of other sources of bias.
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Bush 1994
Methods Randomised controlled trial.
Participants 30 pregnant women with positive cervical Chlamydia trachomatis screen analysed by
direct DNA assay.
15 were randomised to azithromycin.
15 were randomised to erythromycin.
Interventions Erythromycin 500 mg orally 4 times a day for 7 days versus azithromycin 1 g orally as a
single dose
Outcomes Cure rate, side effects.
Notes In those intolerant to erythromycin, 500 mg 4 times daily the dosage was lowered to
250 mg 4 times daily. This occurred in 5 of the 15 erythromycin cases
1 of the patients treated with erythromycin whowas intolerant got positive culture results
after treatment, but was successfully treated with azithromycin
Sexual partners were treated in the standard fashion with doxycycline, 100 mg orally
twice a day for 7 days
Site of study not directly described but assumed to be Willian Beaumont Army Medical
Center, El Paso, Texas
Sources of trial funding: No funding source was declared.
Declarations of interest: Not reported.
Trial dates: Not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated number assignment.
Allocation concealment (selection bias) Low risk Thewomenwere assigned treatment in sealed envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described, unlikely.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data.
Selective reporting (reporting bias) Low risk No selective reporting noted.
Other bias Low risk The study appears to be free of other sources of bias.
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Edwards 1996
Methods Randomised controlled trial.
Participants 140 pregnant women were enrolled. Patients were tested positive for C.trachomatis by
DNA hybridisation from a cervical swab specimen.
Exclusion criteria; allergy to or intolerance of either azithromycin or erythromycin
65 were randomised to azithromycin.
65 were randomised to erythromycin.
Interventions Azithromycin orally 1 g taken orally at enrolment versus erythromycin 500 mg orally 4
times a day for 7 days
Outcomes Cure rate, preterm birth, preterm rupture of membranes, side effects
Notes Compliance for the azithromycin group was 100%.
Compliance for the erythromycin group was 59.4%.
All sexual partners were referred to the appropriate county health department for treat-
ment
Test of cure was repeated after 2 weeks.
62 of the 65 patients in the azithromycin group completed their post-treatment ques-
tionnaires, while 64 of the 65 patients in the erythromycin group completed the same
form
Study was undertaken at the Medical University of South Carolina, Charleston, USA
Sources of trial funding: Sponsored by Pfizer pharmaceuticals.
Declarations of interest: Not reported.
Trial dates: April 1993 - July 1994.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was done using a pre-established ran-
dom number table
Allocation concealment (selection bias) Unclear risk Not described.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No attempt was made to blind the study.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Missing outcome data balanced in numbers across in-
tervention groups, 3 in the azithromycin group and 1 in
the erythromycin group
Selective reporting (reporting bias) Low risk No selective reporting noted.
38Interventions for treating genital Chlamydia trachomatis infection in pregnancy (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Edwards 1996 (Continued)
Other bias High risk There was an unexplained significant difference in mean
gestational age of 8.2 weeks between the 2 treatment
groups (erythromycin 28.6 weeks; azithromycin 20.4
weeks)
Gunter 1996
Methods Randomised controlled trial.
Participants 47 pregnant women with positive Gen-probe test for C.trachomatis were enrolled.
Outcome data were available for 22 who were assigned to the azithromycin group and18
were assigned to the erythromycin group
Interventions Erythromycin 500 mg 4 times a day for 7 days versus azithromycin powder 1 g orally
once
Outcomes Cure rate, side effects.
Notes Treatment compliance was 100% in the azithromycin group and 44.5% in the ery-
thromycin group
Patients unable to tolerate original randomisation due to gastrointestinal side effects were
allowed to cross-over to the opposite study medication
7 patients were excluded due to severe side effects from erythromycin and required cross-
over to azithromycin
Not directly stated but assumed that the study was undertaken at the Bowman Gray
School of Medicine, Winston-Salem, NC, USA
In published abstract it states it is an ongoing trial but no further publications were
found
Sources of trial funding: No funding source was declared.
Declarations of interest: Not reported.
Trial dates: Not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described.
Allocation concealment (selection bias) Unclear risk Not described.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described.
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Gunter 1996 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Insufficient reporting of attrition/exclusions to permit
judgement of ‘Low risk’ or ‘High risk’
Selective reporting (reporting bias) Unclear risk States it is an ongoing trial but no further results have
been published or presented
Other bias Low risk The study appears to be free of other sources of bias.
Jacobson 2001
Methods Randomised controlled trial.
Participants 129 pregnant women with positive cervical C.trachomatis DNA test result were enrolled.
Exclusion criteria included known allergy or hypersensitivity to amoxicillin, penicillin, or
azithromycin; severe hyperemesis gravidarum at the time of entry; and concurrent use of
an antibiotic with efficacy against Chlamydia trachomatis (fluoroquinolones, macrolides,
clindamycin, tetracyclines, or sulphonamides)
110 completed the trial protocol.
55 were in the amoxicillin group and 55 were in the azithromycin group
Interventions Amoxicillin 500 mg orally 3 times a day for 7 days versus azithromycin 1 g once
Outcomes Cure rate, preterm birth.
Notes The study was closed due to realisation that 3000 participants would be needed to
complete it. The number of patients studied were too few. Data presented here include
accrued cure rates for all patients studied
Among the 19 women excluded from the analysis, 14 were lost to follow-up, (8 amox-
icillin, 6 azithromycin) and 5 were involved in protocol violations (3 amoxicillin, 2
azithromycin)
In the amoxicillin group, 3 patients were intolerant to treatment and in the azithromycin
group, 6 patients were intolerant to treatment
Only 35% of the subjects were seen within 7 days of the scheduled appointment for test
of cure
Study was undertaken in 2 university-based inner-city clinics in Milwaukee, USA
Sources of trial funding: No funding source was declared.
Declarations of interest: Not reported.
Trial dates: Ocotber 1988 - February 2000.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was accomplished with a computer-gen-
erated random-number table in blocks of 10
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Jacobson 2001 (Continued)
Allocation concealment (selection bias) Low risk Treatment assignments were placed in sequentially num-
bered, opaque, sealed envelopes by staff not involved in
enrolment, treatment, or evaluation
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Assignments were not blinded, and there was no attempt
to directly visualise patients taking their first dose of
medication
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Of the 19 women excluded from analysis, 14 were lost
to follow-up (8 amoxicillin, 6 azithromycin), but no rea-
sons were provided
Selective reporting (reporting bias) Low risk No selective reporting noted.
Other bias Low risk The study appears to be free of other sources of bias.
Kacmar 2001
Methods Randomised controlled trial.
Participants 39 pregnant women. Routine Chlamydia screens using ligase chain reaction were per-
formed on all patients attending
Exclusion criteria: other infections requiring antibiotic therapy, known allergy or sensi-
tivity to either amoxicillin or azithromycin, or gestational age greater than 33 weeks
19 received amoxicillin and 20 received azithromycin.
Interventions Azithromycin 1 g orally as a single dose versus amoxicillin 500 mg orally 3 times a day
for 7 days
Outcomes Cure rate, repeated infection, side effects.
Notes A referral for treatmentwas given to all partners of patients testing positive forChlamydia,
and patients were instructed to abstain from sexual intercourse until treatment was
completed
Compliance in the azithromycin group was 100%.
Compliance in the amoxicillin group was 84%.
A sample-size calculation was performed, showing that 50 patients would be needed for
each treatment group, but due to limitations and difficulties with recruitment only 39
were enrolled in this trial
The 1 positive test in the azithromycin group was in a patient who did not refer her
partner for treatment, continued to have sexual intercourse and did not use a condom
as recommended
Totals in table 2 vary due to missing data.
Study was undertaken at the Women and Infants Hospital prenatal clinic, Providence,
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Kacmar 2001 (Continued)
USA
Sources of trial funding: Funded by a NIH grant.
Declarations of interest: Not reported.
Trial dates: November 1998 - May 2000.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was performed using a random number
sequence.
Allocation concealment (selection bias) Low risk Opaque envelopes were used for concealment.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Four women in the amoxicillin group and one in the
azithromycin group failed to return for follow-up test of
cure and the reasons are not provided
Selective reporting (reporting bias) Low risk No selective reporting noted.
Other bias Low risk The study appears to be free of other sources of bias.
Magat 1993
Methods Randomised controlled trial.
Participants 143 pregnant women with posItive culture for Chlamydia trachomatis enrolled before
36 weeks’ gestation. Exlusion criteria: sensitivity to either study medication, persistent
gastrointestinal symptoms or history of colitis or antibiotic therapy after screening and
before enrolment
72 were randomised to amoxicillin and 71 to erythromycin.
Interventions Erythromycin (500 mg 4 times daily for 7 days) and amoxicillin (500 mg 3 times a day
for 7 days)
Outcomes Cure rate, side effects of treatment.
Notes Partners of all women received doxycycline (100 mg twice a day for 7 days)
15 in the erythromycin group were intolerant to the therapy. 1 woman in the amoxicillin
group was intolerant to the therapy. In both groups, this intolerance to therapy was
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Magat 1993 (Continued)
developed the first or second day of treatment
Of the 15 who were intolerant to erythromycin, 11 were treated successfully with amox-
icillin, 1 needed a further course of treatment, 2 refused further treatment and 1 was
treated but not tested before delivery
2 of the 9 failures reported partner non-compliance with the doxycycline medication
Study was undertaken in by the University of Maryland School of Medicine, Baltimore,
USA from October 1990 to August 1991
Sources of trial funding: No funding source was declared.
Declarations of interest: Not reported.
Trial dates: October 1990 - August 1991.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation by pseudo-random number generator.
Allocation concealment (selection bias) Low risk The medications were dispensed by the hospital phar-
macy to prevent the healthcare team from learning the
assigned medication or dosage schedule
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 114 completed follow-up (80% completed the study).
Missingdata in the amoxicillin group: out of 72 enrolled,
8 women were excluded. 7 had no follow-up culture
done before delivery. 5 of the 7 delivered before a test
of cure was obtained; 1 woman was mistakenly entered
into the study at 38.5 weeks; and the final woman was
excluded because she was admitted with preterm labour
and given erythromycin before the test of cure. 1 of the
women had a allergic reaction and was also excluded.
64/72 finished treatment (88%)
Missing data in the erythromycin group: out of 71 en-
rolled, 21 women were excluded. 6 women had no fol-
low-up culture for test of cure. 4 of these 6 had deliv-
ered before a test of cure culture was obtained, 1 had a
therapeutic abortion, and 1 moved out of the state. 15
were intolerant to erythromycin and were excluded. In
conclusion 50/71 finished treatment (70%)
Selective reporting (reporting bias) Low risk No selective reporting noted.
43Interventions for treating genital Chlamydia trachomatis infection in pregnancy (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Magat 1993 (Continued)
Other bias High risk There was an unexplained significant difference in the
mean gestational age at entry between the amoxicillin
group (24.0 ± 8.4 weeks) and the erythromycin group
(20.8 ± 8.0 weeks)(P = .05).
Martin 1997
Methods Randomised controlled trial.
Participants 414pregnantwomen, between the 23rd and26thweek of pregnancy,whowere diagnosed
with positive reading of fluorescent isothiocyanate-conjugated Chlamydia trachomatis-
specificmonoclonal antibodywere enrolled.Womenwere eligible if theywere:more than
16 years old, were free of medical complications related to premature delivery, and were
not taking selected medications. Women with positive screening cultures for Neisseria
gonorrhoeae or > l0s micro-organisms/mL of urine were treated and thus ineligible for
the trial
205 women were randomised to the erythromycin group.
209 women were randomised to the placebo group.
Interventions Erythromycin 333 mg orally 3 times daily versus an identical placebo
Outcomes Cure rate, preterm birth, preterm rupture of membranes, side effects, perinatal mortality,
low birthweight
Notes Trial participants with Chlamydia trachomatis were re-treated with doxycycline, tetra-
cycline, or erythromycin immediately postpartum, regardless of which trial medication
they received. Infants were either treated empirically after delivery or were followed,
cultured at their first postnatal visit, and treated with antibiotics if indicated.
Eligible women who agreed to participate in the clinical trial entered a week placebo run-
in. Those who took less than two-thirds of the allotted placebo pills during the run-in,
who did not return to the clinic or refused further participation were not randomised.
Women identified as colonised with Ureaplasma urealyticum,group B streptococci, and/
or Chlamydia trachomatis were considered for randomisation into the clinical trial. We
included only the Chlamydia trachomatis results.
The study have different amounts of missing data on different outcomes
25 erythromycin-treated and 23 placebo-treated women withdrew from the trial but
were included in the intent-to-treat analysis.
The primary outcome was measured mid-treatment.
The 20% failure rate of erythromycin in our study suggests the dose is less than optimal,
possibly due to the 40% increase in blood and extracellular volume in pregnancy acting
to reduce serum and tissue drug levels
Study was undertaken in 7 institutions utilising 6 antepartum clinics in Harlem Hospi-
tal, New York, Columbia University, New York, Louisiana State University and Tulane
University, New Orleans, University of Oklahoma, Oklahoma City, University of Texas,
San Antonio and University of Washington, Seattle, USA
Sources of trial funding: This work was supported by contracts from the National
Institute of Child Health and HumanDevelopment ant theNational Institute of Allergy
and Infectious Diseases
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Martin 1997 (Continued)
Declarations of interest: Not reported.
Trial dates: November 1984 - March 1989.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Balanced randomisation scheme by Research Triangle
Institute: computer randomised according to permuted-
block procedure with randomblock sizes. (Reference 13)
Allocation concealment (selection bias) Unclear risk Not described. Identical placebo.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 48 (11.6%) withdrew from the trial. Different amount
of data missing in different aspects of outcomes
Selective reporting (reporting bias) Low risk No selective reporting noted.
Other bias Low risk The study appears to be free of other sources of bias.
Rosenn 1995
Methods Randomised controlled trial.
Participants 48 pregnant women with positive culture of Chlamydia trachomatis were enrolled.
24 were randomised to receive erythromycin and 24 were randomised to receive azithro-
mycin
Interventions Azithromycin single dose 1 g orally versus erythromycin 500 mg 4 times daily for 7 days
orally
Outcomes Cure rate, side effects.
Notes All partners received doxycycline 100 mg twice a day orally.
Follow-up meeting 3 weeks after therapy. Compliance was then measured by pill count
and the participants had filled out a questionnaire about: sexual activity, side effects and
compliance.
Azithromycin group compliance: 100%.
Erythromycin group compliance: 61%.
Study was undertaken at Thomas JeffersonUniversityHospital prenatal clinics, Philadel-
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Rosenn 1995 (Continued)
phia, USA, from August 1994 to April 1995
Sources of trial funding: no funding source reported.
Declarations of interest: Not reported.
Trial dates: Not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block of 6 randomisation generated from a random-
number table
Allocation concealment (selection bias) Low risk Sequentially numbered, sealed opaque envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not mentioned.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3 were lost to follow-up (94% completed the study).
Selective reporting (reporting bias) Low risk No selective reporting noted.
Other bias Low risk The study appears to be free of other sources of bias.
Silverman 1994
Methods Randomised controlled trial.
Participants 74 pregnant women with culture positive Chlamydia trachomatis infection. Excluded if
the first prenatal visit was after 36 weeks, recent antibiotic use for another indication
(within 14 days), and known allergy or sensitivity to either of the study medications
36 were treated with amoxicillin.
38 were treated with erythromycin.
Interventions Amoxicillin 500 mg orally 3 times a day or erythromycin 500 mg orally 4 times daily
for 7 days
Outcomes Cure rate, side effects.
Notes The women who did not cure from the first dosage were crossed over to the alternative
treatment. These results are not included in our analysis
Partners were treated with doxycycline 100 mg orally twice a day for 7 days
Study was undertaken at Thomas JeffersonUniversityHospital prenatal clinics, Philadel-
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Silverman 1994 (Continued)
phia, USA
Sources of trial funding: no funding source reported.
Declarations of interest: Not reported.
Trial dates: Not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block of 6 randomisation generated from a random-
number table
Allocation concealment (selection bias) Low risk Sequentially numbered opaque envelopes.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 4 women in each group were lost to follow-up and no
reasons were provided
Selective reporting (reporting bias) Low risk No selective reporting noted.
Other bias Low risk The study appears to be free of other sources of bias.
Turrentine 1995
Methods Randomised controlled trial.
Participants 168 pregnant women, < 36 weeks’ gestation, with positive cervicalChlamydia trachomatis
culture were enrolled.
56 received erythromycin, 57 received amoxicillin and 55 received clindamycin
Interventions Erythromycin-base tablets 500 mg orally 4 times a day for 7 days, amoxicillin capsules
500 mg 2 times a day for 7 days or clindamycin tablets 600 mg orally 2 times a day for
10 days
Outcomes Cure rate, side effects.
Notes All sexual partners in the study was offered treatment with doxycycline 100 mg twice a
day for 7 days.
There were no statistically significant differences in age, racial distribution, gravidity,
gestational age, or number of days to test-of-cure among the groups
6 women elected not to participate.
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Turrentine 1995 (Continued)
8 patients were lost to follow-up, 3 in the erythromycin, 2 in the amoxicillin, and 3 in
the clindamycin group, and were excluded from the analysis
5 women in the erythromycin group had severe side effects and discontinued the treat-
ment
In the amoxicillin group, 2 women had severe side effects and discontinued the treatment
In the clindamycin group 2 women developed an allergic reaction to clindamycin and
had to discontinue. 2 women had severe side effects to the treatment and discontinued
1 developed an allergic reaction to erythromycin and had to discontinue
Study was undertaken by the University of Texas Health Science Center, Houston, USA
Sources of trial funding: Pharmaceutical companies Parke-Davis, Lederle and Upjohn
supplied the treatment medications
Declarations of interest: Not reported.
Trial dates: July 1991 - September 1993.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisationwas accomplished by computer-gen-
erated assignment
Allocation concealment (selection bias) Low risk Unlabelled medications.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The unlabeled medications were dispensed by the hospi-
tal pharmacy to prevent the healthcare team from learn-
ing the assigned medication
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All participants had test of cure, assessors were still
blinded to treatment group
Incomplete outcome data (attrition bias)
All outcomes
Low risk 148 (85%) completed the protocol. Missing outcome
data balanced in numbers across intervention groups,
with similar reasons for missing data across groups
Selective reporting (reporting bias) Low risk No selective reporting noted.
Other bias Low risk The study appears to be free of other sources of bias.
Wehbeh 1998
Methods Randomised controlled trial.
Participants 48 pregnant women screening positive for fluorescein-conjugated monoclonal antibody
toChlamydia trachomatis were enrolled.
17 received azithromycin and their partners received azithromycin, 10 received azithro-
mycin and their partners received tetracycline and 21 received erythromycin and the
partner received azithromycin
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Wehbeh 1998 (Continued)
For this analysis the azithromycin group was considered as one group (27 women) and
was compared to the erythromycin group (21 women)
Interventions 3 groups. Single dose of azithromycin 1 g orally (partners got the same), erythromycin
500 mg orally 3 times a day for 7 days (partners got tetracycline) and single dose of
azithromycin 1 g orally (partners got tetracycline)
Outcomes Cure rate, side effects.
Notes 7-10 days after treatment started compliance was controlled by having a meeting with
the couples. They were asked to bring their medication bottles and if it had at least 1
day of unused medications in it, the couple was considered non-compliant.
Compliance rates: azithromycin: 92.6%(2 refused toparticipate after the randomisation)
, erythromycin: 71.4%, tetracycline: 75%.
There was no significant difference in age, gestational age at entry into the study or
number of prior pregnancies between treatment groups.
Only 12% in group 1 reported having sexual intercourse during the study period whilst
42.9% and 30% in group 2 and 3 did.
Exact multiple logistic regression procedures was used to see if the treatment failure was
due to reinfection from their sexual activity during the study. It showed no confounding
of the observed treatment groups and is used as evidence that treatment failure is not
due to reinfection of sexual partner
The third treatment group was included in order to assess the efficacy of multidose course
of tetracycline versus single-dose therapy with azithromycin, and to indirectly assess the
possible reinfection of the pregnant women through sexual intercourse during the trial
period.
They considered that they did not need to make all the medications look the same and
just placebo pills to make the azithromycin treatment identical to erythromycin because
they thought compliance bias would be introduced
Study was undertaken in a prenatal clinic located within a large urban medical centre
with New York, USA
Sources of trial funding: the trial was funded by local department funds.
Declarations of interest: Not reported.
Trial dates: Not reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described.
Allocation concealment (selection bias) Unclear risk Not described.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk States all participants were unaware of the exact nature
of the antibiotic treatment given to them but that no
placebo was used
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Wehbeh 1998 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 in the first study group refusedmedications (96%com-
pleted the study)
Selective reporting (reporting bias) Low risk No selective reporting noted.
Other bias Low risk The study appears to be free of other sources of bias.
g: gram
mg: milligram
mL: millilitre
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
El-Shourbagy 2011 This study examines the rate of pre-eclampsia in groups of treated and non-treated Chlamydia pneumoniae
infections in pregnancy.
McGregor 1990 This study included pregnant women with various genital tract infections and not only C.trachomatis. The
data for C.trachomatis infection were not presented separately.
Nadafi 2005 Not all participants of this trial had C.trachomatis infection, therefore, the study was excluded.
Zulkarneev 1998 This study was not a randomised controlled trial.
Characteristics of ongoing studies [ordered by study ID]
Okunola 2013
Trial name or title Treatment of antenatal Chlamydia infection.
Methods Randomised controlled trial.
Open label.
Participants Pregnant women at less than 36 weeks’ gestation with positive C.trachomatis test on endocervical swab with
rapid kit.
Exlcuded with history of antibiotics in the last 2 weeks or low lying placenta, history of reaction to any of the
drugs
Plan to recruit 200 participants.
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Okunola 2013 (Continued)
Interventions Group 1 - amoxicillin 500 mg orally 3 times a day for a week
Group 2 - erythromycin 500 mg 4 times a day for a week.
Partners were treated with doxycycline for a week.
Outcomes Completiion of course treatment.
Microbiological cure.
Side effects (nausea, diarrhoea, vomiting, loss of appetite)
Starting date October 2013.
Contact information Obafemi Awolowo University Teaching Hospital.
Notes Clinical Trial identifier NCT01946256.
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D A T A A N D A N A L Y S E S
Comparison 1. Erythromycin versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Microbiological cure 2 495 Risk Ratio (M-H, Random, 95% CI) 2.64 [1.60, 4.38]
2 Preterm birth 1 405 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.56, 1.46]
3 Preterm rupture of membranes 1 389 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.48, 1.43]
4 Side effects of treatment 2 495 Risk Ratio (M-H, Random, 95% CI) 2.93 [0.36, 23.76]
5 Perinatal mortality 1 405 Risk Ratio (M-H, Fixed, 95% CI) 3.01 [0.32, 28.74]
6 Low birthweight 1 400 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.42, 1.40]
Comparison 2. Clindamycin versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Microbiological cure 1 85 Risk Ratio (M-H, Fixed, 95% CI) 4.08 [2.35, 7.08]
2 Side effects of treatment 1 85 Risk Ratio (M-H, Fixed, 95% CI) 5.37 [0.65, 44.01]
Comparison 3. Amoxicillin versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Microbiological cure 1 15 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.59, 6.79]
Comparison 4. Amoxicillin versus azithromycin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Microbiological cure 2 144 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.71, 1.12]
2 Repeated infection 1 34 Risk Ratio (M-H, Fixed, 95% CI) 0.42 [0.02, 9.55]
3 Preterm birth 1 90 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.43, 3.20]
4 Side effects of treatment 1 36 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.24, 1.31]
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Comparison 5. Amoxicillin versus erythromycin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Microbiological cure 4 466 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.93, 1.01]
2 Side effects of treatment 4 513 Risk Ratio (M-H, Fixed, 95% CI) 0.31 [0.21, 0.46]
Comparison 6. Azithromycin versus erythromycin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Microbiological cure 6 374 Risk Ratio (M-H, Random, 95% CI) 1.11 [1.00, 1.23]
2 Repeated infection 1 85 Risk Ratio (M-H, Fixed, 95% CI) 1.37 [0.32, 5.73]
3 Preterm birth 1 126 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.29, 2.10]
4 Preterm rupture of membranes 1 126 Risk Ratio (M-H, Fixed, 95% CI) 0.62 [0.15, 2.48]
5 Side effects of treatment 6 374 Risk Ratio (M-H, Fixed, 95% CI) 0.24 [0.17, 0.34]
Comparison 7. Clindamycin versus erythromycin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Microbiological cure 2 173 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.97, 1.15]
2 Side effects of treatment 2 183 Risk Ratio (M-H, Fixed, 95% CI) 0.44 [0.22, 0.87]
Comparison 8. Amoxicillin versus clindamycin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Microbiological cure 1 101 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.89, 1.04]
2 Side effects of treatment 1 107 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.14, 2.26]
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Analysis 1.1. Comparison 1 Erythromycin versus placebo, Outcome 1 Microbiological cure.
Review: Interventions for treating genital Chlamydia trachomatis infection in pregnancy
Comparison: 1 Erythromycin versus placebo
Outcome: 1 Microbiological cure
Study or subgroup Erythromycin Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Alger 1991 31/37 10/44 37.1 % 3.69 [ 2.10, 6.47 ]
Martin 1997 164/205 77/209 62.9 % 2.17 [ 1.80, 2.63 ]
Total (95% CI) 242 253 100.0 % 2.64 [ 1.60, 4.38 ]
Total events: 195 (Erythromycin), 87 (Placebo)
Heterogeneity: Tau2 = 0.10; Chi2 = 3.08, df = 1 (P = 0.08); I2 =68%
Test for overall effect: Z = 3.78 (P = 0.00016)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours placebo Favours erythomycin
Analysis 1.2. Comparison 1 Erythromycin versus placebo, Outcome 2 Preterm birth.
Review: Interventions for treating genital Chlamydia trachomatis infection in pregnancy
Comparison: 1 Erythromycin versus placebo
Outcome: 2 Preterm birth
Study or subgroup Erythromycin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Martin 1997 27/202 30/203 100.0 % 0.90 [ 0.56, 1.46 ]
Total (95% CI) 202 203 100.0 % 0.90 [ 0.56, 1.46 ]
Total events: 27 (Erythromycin), 30 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Erythromycin Favours Placebo
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Analysis 1.3. Comparison 1 Erythromycin versus placebo, Outcome 3 Preterm rupture of membranes.
Review: Interventions for treating genital Chlamydia trachomatis infection in pregnancy
Comparison: 1 Erythromycin versus placebo
Outcome: 3 Preterm rupture of membranes
Study or subgroup Erythromycin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Martin 1997 21/196 25/193 100.0 % 0.83 [ 0.48, 1.43 ]
Total (95% CI) 196 193 100.0 % 0.83 [ 0.48, 1.43 ]
Total events: 21 (Erythromycin), 25 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.49)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Erytromycin Favours Placebo
Analysis 1.4. Comparison 1 Erythromycin versus placebo, Outcome 4 Side effects of treatment.
Review: Interventions for treating genital Chlamydia trachomatis infection in pregnancy
Comparison: 1 Erythromycin versus placebo
Outcome: 4 Side effects of treatment
Study or subgroup Erythromycin Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Alger 1991 9/37 1/44 39.0 % 10.70 [ 1.42, 80.62 ]
Martin 1997 113/205 90/209 61.0 % 1.28 [ 1.05, 1.56 ]
Total (95% CI) 242 253 100.0 % 2.93 [ 0.36, 23.76 ]
Total events: 122 (Erythromycin), 91 (Placebo)
Heterogeneity: Tau2 = 1.86; Chi2 = 4.47, df = 1 (P = 0.03); I2 =78%
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
Favours Erythromycin Favours Placebo
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Analysis 1.5. Comparison 1 Erythromycin versus placebo, Outcome 5 Perinatal mortality.
Review: Interventions for treating genital Chlamydia trachomatis infection in pregnancy
Comparison: 1 Erythromycin versus placebo
Outcome: 5 Perinatal mortality
Study or subgroup Erythromycin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Martin 1997 3/202 1/203 100.0 % 3.01 [ 0.32, 28.74 ]
Total (95% CI) 202 203 100.0 % 3.01 [ 0.32, 28.74 ]
Total events: 3 (Erythromycin), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Erythromycin Favours Placebo
Analysis 1.6. Comparison 1 Erythromycin versus placebo, Outcome 6 Low birthweight.
Review: Interventions for treating genital Chlamydia trachomatis infection in pregnancy
Comparison: 1 Erythromycin versus placebo
Outcome: 6 Low birthweight
Study or subgroup Erythromycin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Martin 1997 17/201 22/199 100.0 % 0.77 [ 0.42, 1.40 ]
Total (95% CI) 201 199 100.0 % 0.77 [ 0.42, 1.40 ]
Total events: 17 (Erythromycin), 22 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.87 (P = 0.38)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Erythromycin Favours Placebo
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Analysis 2.1. Comparison 2 Clindamycin versus placebo, Outcome 1 Microbiological cure.
Review: Interventions for treating genital Chlamydia trachomatis infection in pregnancy
Comparison: 2 Clindamycin versus placebo
Outcome: 1 Microbiological cure
Study or subgroup Clindamycin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Alger 1991 38/41 10/44 100.0 % 4.08 [ 2.35, 7.08 ]
Total (95% CI) 41 44 100.0 % 4.08 [ 2.35, 7.08 ]
Total events: 38 (Clindamycin), 10 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 4.99 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours placebo Favours clindamycin
Analysis 2.2. Comparison 2 Clindamycin versus placebo, Outcome 2 Side effects of treatment.
Review: Interventions for treating genital Chlamydia trachomatis infection in pregnancy
Comparison: 2 Clindamycin versus placebo
Outcome: 2 Side effects of treatment
Study or subgroup Clindamycin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Alger 1991 5/41 1/44 100.0 % 5.37 [ 0.65, 44.01 ]
Total (95% CI) 41 44 100.0 % 5.37 [ 0.65, 44.01 ]
Total events: 5 (Clindamycin), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.56 (P = 0.12)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Clindamycin Favours Placebo
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Analysis 3.1. Comparison 3 Amoxicillin versus placebo, Outcome 1 Microbiological cure.
Review: Interventions for treating genital Chlamydia trachomatis infection in pregnancy
Comparison: 3 Amoxicillin versus placebo
Outcome: 1 Microbiological cure
Study or subgroup Amoxicillin Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bell 1982 6/9 2/6 100.0 % 2.00 [ 0.59, 6.79 ]
Total (95% CI) 9 6 100.0 % 2.00 [ 0.59, 6.79 ]
Total events: 6 (Amoxicillin), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours placebo Favours amoxicillin
Analysis 4.1. Comparison 4 Amoxicillin versus azithromycin, Outcome 1 Microbiological cure.
Review: Interventions for treating genital Chlamydia trachomatis infection in pregnancy
Comparison: 4 Amoxicillin versus azithromycin
Outcome: 1 Microbiological cure
Study or subgroup Amoxicillin Azithromycin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Jacobson 2001 32/55 35/55 68.8 % 0.91 [ 0.68, 1.23 ]
Kacmar 2001 12/15 18/19 31.2 % 0.84 [ 0.64, 1.11 ]
Total (95% CI) 70 74 100.0 % 0.89 [ 0.71, 1.12 ]
Total events: 44 (Amoxicillin), 53 (Azithromycin)
Heterogeneity: Chi2 = 0.18, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours Azithromycin Favours Amoxicillin
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Analysis 4.2. Comparison 4 Amoxicillin versus azithromycin, Outcome 2 Repeated infection.
Review: Interventions for treating genital Chlamydia trachomatis infection in pregnancy
Comparison: 4 Amoxicillin versus azithromycin
Outcome: 2 Repeated infection
Study or subgroup Amoxicillin Azithromycin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kacmar 2001 0/15 1/19 100.0 % 0.42 [ 0.02, 9.55 ]
Total (95% CI) 15 19 100.0 % 0.42 [ 0.02, 9.55 ]
Total events: 0 (Amoxicillin), 1 (Azithromycin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Amoxicillin Favours Azithromycin
Analysis 4.3. Comparison 4 Amoxicillin versus azithromycin, Outcome 3 Preterm birth.
Review: Interventions for treating genital Chlamydia trachomatis infection in pregnancy
Comparison: 4 Amoxicillin versus azithromycin
Outcome: 3 Preterm birth
Study or subgroup Amoxicillin Azithromycin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Jacobson 2001 7/45 6/45 100.0 % 1.17 [ 0.43, 3.20 ]
Total (95% CI) 45 45 100.0 % 1.17 [ 0.43, 3.20 ]
Total events: 7 (Amoxicillin), 6 (Azithromycin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.30 (P = 0.76)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Amoxicillin Favours Azithromycin
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Analysis 4.4. Comparison 4 Amoxicillin versus azithromycin, Outcome 4 Side effects of treatment.
Review: Interventions for treating genital Chlamydia trachomatis infection in pregnancy
Comparison: 4 Amoxicillin versus azithromycin
Outcome: 4 Side effects of treatment
Study or subgroup Amoxicillin Azithromycin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Kacmar 2001 5/17 10/19 100.0 % 0.56 [ 0.24, 1.31 ]
Total (95% CI) 17 19 100.0 % 0.56 [ 0.24, 1.31 ]
Total events: 5 (Amoxicillin), 10 (Azithromycin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Amoxicillin Favours Azithromycin
Analysis 5.1. Comparison 5 Amoxicillin versus erythromycin, Outcome 1 Microbiological cure.
Review: Interventions for treating genital Chlamydia trachomatis infection in pregnancy
Comparison: 5 Amoxicillin versus erythromycin
Outcome: 1 Microbiological cure
Study or subgroup Amoxicillin Erythromycin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Alary 1994 98/99 87/87 42.0 % 0.99 [ 0.96, 1.02 ]
Magat 1993 55/64 47/50 23.8 % 0.91 [ 0.81, 1.03 ]
Silverman 1994 28/34 27/32 12.6 % 0.98 [ 0.79, 1.21 ]
Turrentine 1995 50/53 45/47 21.5 % 0.99 [ 0.90, 1.08 ]
Total (95% CI) 250 216 100.0 % 0.97 [ 0.93, 1.01 ]
Total events: 231 (Amoxicillin), 206 (Erythromycin)
Heterogeneity: Chi2 = 3.18, df = 3 (P = 0.36); I2 =6%
Test for overall effect: Z = 1.34 (P = 0.18)
Test for subgroup differences: Not applicable
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Analysis 5.2. Comparison 5 Amoxicillin versus erythromycin, Outcome 2 Side effects of treatment.
Review: Interventions for treating genital Chlamydia trachomatis infection in pregnancy
Comparison: 5 Amoxicillin versus erythromycin
Outcome: 2 Side effects of treatment
Study or subgroup Amoxicillin Erythromycin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Alary 1994 15/99 34/99 38.0 % 0.44 [ 0.26, 0.76 ]
Magat 1993 5/65 30/65 33.6 % 0.17 [ 0.07, 0.40 ]
Silverman 1994 5/39 12/38 13.6 % 0.41 [ 0.16, 1.04 ]
Turrentine 1995 3/55 13/53 14.8 % 0.22 [ 0.07, 0.74 ]
Total (95% CI) 258 255 100.0 % 0.31 [ 0.21, 0.46 ]
Total events: 28 (Amoxicillin), 89 (Erythromycin)
Heterogeneity: Chi2 = 4.13, df = 3 (P = 0.25); I2 =27%
Test for overall effect: Z = 5.89 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 6.1. Comparison 6 Azithromycin versus erythromycin, Outcome 1 Microbiological cure.
Review: Interventions for treating genital Chlamydia trachomatis infection in pregnancy
Comparison: 6 Azithromycin versus erythromycin
Outcome: 1 Microbiological cure
Study or subgroup Azithromycin Erythromycin Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Adair 1998 37/42 40/43 20.9 % 0.95 [ 0.82, 1.09 ]
Bush 1994 15/15 14/15 16.6 % 1.07 [ 0.89, 1.28 ]
Edwards 1996 58/62 46/64 17.9 % 1.30 [ 1.10, 1.54 ]
Gunter 1996 22/22 17/18 20.1 % 1.06 [ 0.92, 1.23 ]
Rosenn 1995 21/23 17/22 11.0 % 1.18 [ 0.91, 1.53 ]
Wehbeh 1998 26/27 17/21 13.4 % 1.19 [ 0.95, 1.48 ]
Total (95% CI) 191 183 100.0 % 1.11 [ 1.00, 1.23 ]
Total events: 179 (Azithromycin), 151 (Erythromycin)
Heterogeneity: Tau2 = 0.01; Chi2 = 10.56, df = 5 (P = 0.06); I2 =53%
Test for overall effect: Z = 1.87 (P = 0.061)
Test for subgroup differences: Not applicable
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Analysis 6.2. Comparison 6 Azithromycin versus erythromycin, Outcome 2 Repeated infection.
Review: Interventions for treating genital Chlamydia trachomatis infection in pregnancy
Comparison: 6 Azithromycin versus erythromycin
Outcome: 2 Repeated infection
Study or subgroup Azithromycin Erythromycin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Adair 1998 4/42 3/43 100.0 % 1.37 [ 0.32, 5.73 ]
Total (95% CI) 42 43 100.0 % 1.37 [ 0.32, 5.73 ]
Total events: 4 (Azithromycin), 3 (Erythromycin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.67)
Test for subgroup differences: Not applicable
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Analysis 6.3. Comparison 6 Azithromycin versus erythromycin, Outcome 3 Preterm birth.
Review: Interventions for treating genital Chlamydia trachomatis infection in pregnancy
Comparison: 6 Azithromycin versus erythromycin
Outcome: 3 Preterm birth
Study or subgroup Azithromycin Erythromycin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Edwards 1996 6/62 8/64 100.0 % 0.77 [ 0.29, 2.10 ]
Total (95% CI) 62 64 100.0 % 0.77 [ 0.29, 2.10 ]
Total events: 6 (Azithromycin), 8 (Erythromycin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.62)
Test for subgroup differences: Not applicable
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Analysis 6.4. Comparison 6 Azithromycin versus erythromycin, Outcome 4 Preterm rupture of
membranes.
Review: Interventions for treating genital Chlamydia trachomatis infection in pregnancy
Comparison: 6 Azithromycin versus erythromycin
Outcome: 4 Preterm rupture of membranes
Study or subgroup Azithromycin Erythromycin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Edwards 1996 3/62 5/64 100.0 % 0.62 [ 0.15, 2.48 ]
Total (95% CI) 62 64 100.0 % 0.62 [ 0.15, 2.48 ]
Total events: 3 (Azithromycin), 5 (Erythromycin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 6.5. Comparison 6 Azithromycin versus erythromycin, Outcome 5 Side effects of treatment.
Review: Interventions for treating genital Chlamydia trachomatis infection in pregnancy
Comparison: 6 Azithromycin versus erythromycin
Outcome: 5 Side effects of treatment
Study or subgroup Azithromycin Erythromycin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Adair 1998 5/42 25/43 21.1 % 0.20 [ 0.09, 0.48 ]
Bush 1994 0/15 15/15 13.2 % 0.03 [ 0.00, 0.49 ]
Edwards 1996 12/62 42/64 35.2 % 0.29 [ 0.17, 0.51 ]
Gunter 1996 3/22 11/18 10.3 % 0.22 [ 0.07, 0.68 ]
Rosenn 1995 4/23 10/22 8.7 % 0.38 [ 0.14, 1.04 ]
Wehbeh 1998 4/27 12/21 11.5 % 0.26 [ 0.10, 0.69 ]
Total (95% CI) 191 183 100.0 % 0.24 [ 0.17, 0.34 ]
Total events: 28 (Azithromycin), 115 (Erythromycin)
Heterogeneity: Chi2 = 3.71, df = 5 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 7.84 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 7.1. Comparison 7 Clindamycin versus erythromycin, Outcome 1 Microbiological cure.
Review: Interventions for treating genital Chlamydia trachomatis infection in pregnancy
Comparison: 7 Clindamycin versus erythromycin
Outcome: 1 Microbiological cure
Study or subgroup Clindamycin Erythromycin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Alger 1991 38/41 31/37 41.7 % 1.11 [ 0.94, 1.31 ]
Turrentine 1995 47/48 45/47 58.3 % 1.02 [ 0.95, 1.10 ]
Total (95% CI) 89 84 100.0 % 1.06 [ 0.97, 1.15 ]
Total events: 85 (Clindamycin), 76 (Erythromycin)
Heterogeneity: Chi2 = 1.09, df = 1 (P = 0.30); I2 =8%
Test for overall effect: Z = 1.33 (P = 0.18)
Test for subgroup differences: Not applicable
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Analysis 7.2. Comparison 7 Clindamycin versus erythromycin, Outcome 2 Side effects of treatment.
Review: Interventions for treating genital Chlamydia trachomatis infection in pregnancy
Comparison: 7 Clindamycin versus erythromycin
Outcome: 2 Side effects of treatment
Study or subgroup Clindamycin Erythromycin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Alger 1991 5/41 9/37 42.4 % 0.50 [ 0.18, 1.36 ]
Turrentine 1995 5/52 13/53 57.6 % 0.39 [ 0.15, 1.02 ]
Total (95% CI) 93 90 100.0 % 0.44 [ 0.22, 0.87 ]
Total events: 10 (Clindamycin), 22 (Erythromycin)
Heterogeneity: Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 2.34 (P = 0.019)
Test for subgroup differences: Not applicable
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Analysis 8.1. Comparison 8 Amoxicillin versus clindamycin, Outcome 1 Microbiological cure.
Review: Interventions for treating genital Chlamydia trachomatis infection in pregnancy
Comparison: 8 Amoxicillin versus clindamycin
Outcome: 1 Microbiological cure
Study or subgroup Amoxicillin Clindamycin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Turrentine 1995 50/53 47/48 100.0 % 0.96 [ 0.89, 1.04 ]
Total (95% CI) 53 48 100.0 % 0.96 [ 0.89, 1.04 ]
Total events: 50 (Amoxicillin), 47 (Clindamycin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Not applicable
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Analysis 8.2. Comparison 8 Amoxicillin versus clindamycin, Outcome 2 Side effects of treatment.
Review: Interventions for treating genital Chlamydia trachomatis infection in pregnancy
Comparison: 8 Amoxicillin versus clindamycin
Outcome: 2 Side effects of treatment
Study or subgroup Amoxicillin Clindamycin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Turrentine 1995 3/55 5/52 100.0 % 0.57 [ 0.14, 2.26 ]
Total (95% CI) 55 52 100.0 % 0.57 [ 0.14, 2.26 ]
Total events: 3 (Amoxicillin), 5 (Clindamycin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Not applicable
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A P P E N D I C E S
Appendix 1. Search terms for ClinicalTrials.gov and ICTRP
ClinicalTrials.gov
chlamydia AND pregnancy
chlamydia AND pregnant
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
There are some differences between our published protocol (Novikova 2013) and the full review; these are outlined below.
• The contact person for the review has changed from Natalia Novikova to Cathy Cluver.
• We have updated our methods text to include the use of GRADE and we have included eight ’Summary of findings’ tables.
• We have added the WHO International Clinical Trials Registry Platform (ICTRP) to sources searched.
N O T E S
This new review updates and supersedes an earlier review on this topic by Brocklehurst 1998.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Chlamydia trachomatis; Amoxicillin [therapeutic use]; Anti-Bacterial Agents [∗therapeutic use]; Azithromycin [therapeutic use];
Chlamydia Infections [∗drug therapy]; Clindamycin [therapeutic use]; Erythromycin [therapeutic use]; Pregnancy Complications,
Infectious [∗drug therapy; microbiology]; Randomized Controlled Trials as Topic; Reproductive Tract Infections [∗drug therapy]
MeSH check words
Female; Humans; Pregnancy
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